DownloadHi-Res Photo

Roy S. Herbst, MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Deputy Director, Yale Cancer Center; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Assistant Dean for Translational Research, Yale School of Medicine; Director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital

Research & Publications
Biography
News

Research Summary

Dr. Herbst is committed to maintaining Yale’s status as one of the world's top centers for cancer research and patient care, through innovative programs at the cutting edge of science and clinical practice. For example, we have a facility to investigate a patient's cancer at the molecular level giving us key molecular data that our oncologists use to pursue the most promising treatments for our patients as early as possible in the course of their disease.

His work on "umbrella” trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. Nationally, he works closely with public-private partnerships to develop large master protocol clinical studies. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program. and is principal investigator (PI) of the Lung Master Protocol (Lung-MAP). These trials use molecular analysis of fresh tissue biopsies to help match patients to the best novel treatment in real time, and these results provide laboratory scientists the ability to explore and uncover potential resistance mechanisms in the clinic.

Over several decades, biomarkers have been identified that help clinicians target treatment and immunotherapies for patients with corresponding genetic mutations. Dr. Herbst has led teams that brought about the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib), which have revolutionized the field and greatly enhanced patient survival. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. His leadership in targeted therapeutics resulted in a 2020 ASCO plenary talk and publication of results of the third-generation EGFR-inhibitor osimertinib for the treatment of resected EGFR-mutant NSCLC in the New England Journal of Medicine.

Specialized Terms: Early phase clinical trials; Biomarker studies; Personalized medicine for cancer treatment. Immunotherapy for the treatment of cancer.

Coauthors

Research Interests

Lung Neoplasms; Medical Oncology; Thoracic Neoplasms; Clinical Trials, Phase I as Topic; Biomarkers, Pharmacological; Precision Medicine

Public Health Interests

Cancer

Selected Publications

Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURAGrohé C, Tsuboi M, Wu Y, John T, Majem M, Wang J, Kato T, Goldman J, Kim S, Yu C, Vu H, Mukhametshina G, Akewanlop C, de Marinis F, Shepherd F, Urban D, Stachowiak M, Balanos A, Huang X, Herbst R, Kern J. Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA Pneumologie 2023, 77: s17-s17. DOI: 10.1055/s-0043-1760904.
OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA ResultsHerbst R, Wu Y, Grohe C, John T, Majem M, Wang J, Kato T, Goldman J, Kim S, Yu C, Vu H, Mukhametshina G, Akewanlop C, de Marinis F, Shepherd F, Urban D, Stachowiak M, Bolanos A, Huang X, Tsuboi M. OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results Journal Of Thoracic Oncology 2023, 18: e4. DOI: 10.1016/j.jtho.2022.09.125.
Comparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer ImagingJoel M, Avesta A, Yang D, Zhou J, Omuro A, Herbst R, Krumholz H, Aneja S. Comparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer Imaging Cancers 2023, 15: 1548. PMID: 36900339, PMCID: PMC10000732, DOI: 10.3390/cancers15051548.
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.Herbst R, Wu Y, John T, Grohe C, Majem M, Wang J, Kato T, Goldman J, Laktionov K, Kim S, Yu C, Vu H, Lu S, Lee K, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd F, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal Of Clinical Oncology 2023, jco2202186. PMID: 36720083, DOI: 10.1200/jco.22.02186.
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLCMok T, Lopes G, Cho B, Kowalski D, Kasahara K, Wu Y, de Castro G, Turna H, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Pietanza M, Piperdi B, Herbst R. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC Annals Of Oncology 2023 PMID: 36709038, DOI: 10.1016/j.annonc.2023.01.011.
Quality-of-life outcomes and risk prediction for patients randomized to Nivolumab/Ipilimumab vs Nivolumab on LungMAP-S1400I.Unger J, Qian L, Redman M, Tavernier S, Minasian L, Sigal E, Papadimitrakopoulou V, LeBlanc M, Cleeland C, Dzingle S, Summers T, Chao H, Madhusudhana S, Villaruz L, Crawford J, Gray J, Kelly K, Gandara D, Bazhenova L, Herbst R, Gettinger S, Moinpour C. Quality-of-life outcomes and risk prediction for patients randomized to Nivolumab/Ipilimumab vs Nivolumab on LungMAP-S1400I. Journal Of The National Cancer Institute 2023 PMID: 36625510, DOI: 10.1093/jnci/djad003.
29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC)Gandara D, Hua X, Tolba K, Fabrizio D, Albacker L, Brennick R, Montesion M, Oxnard G, Adam S, Hirsch F, Kelly K, Herbst R, LeBlanc M, Redman M, Wu M, Kozono D. 29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC) 2022, a31-a31. DOI: 10.1136/jitc-2022-sitc2022.0029.
584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumabTolba K, Gandara D, Montesion M, Nabet B, Srivastava M, Albacker L, Redman M, Kozono D, Cummings C, Herbst R, Shames D, Fabrizio D. 584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab 2022, a610-a610. DOI: 10.1136/jitc-2022-sitc2022.0584.
635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancerHerbst R, Lam W, Hellmann M, Gubens M, Aggarwal C, Weng Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Finocchiaro G, Ahn M, Luft A, Landers G, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Gutierrez M. 635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer 2022, a665-a665. DOI: 10.1136/jitc-2022-sitc2022.0635.
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.Hayes D, Herbst R, Myles J, Topalian S, Yohe S, Aronson N, Bellizzi A, Basu Roy U, Bradshaw G, Edwards R, El-Gabry E, Elvin J, Gajewski T, McShane L, Oberley M, Philip R, Rimm D, Rosenbaum J, Rubin E, Schlager L, Sherwood S, Stewart M, Taube J, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precision Oncology 2022, 6: e2200454. PMID: 36446042, DOI: 10.1200/po.22.00454.
LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURAJohn T, Grohe C, Goldman J, De Marinis F, Kato T, Wang Q, Choi J, Melotti B, Fidler M, Sainsbury L, Stachowiak M, Taggart S, Wu Y, Tsuboi M, Herbst R, Tarruella M. LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA Annals Of Oncology 2022, 33: s1548. DOI: 10.1016/j.annonc.2022.10.323.
296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURAWu Y, Tsuboi M, Grohe C, John T, Tarruella M, Wang J, Kato T, Goldman J, Kim S, Yu C, Vu H, Mukhametshina G, Akewanlop C, de Marinis F, Shepherd F, Urban D, Stachowiak M, Bolanos A, Huang X, Herbst R. 296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA Annals Of Oncology 2022, 33: s1548-s1549. DOI: 10.1016/j.annonc.2022.10.324.
Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical OncologyHerbst RS, Hatsukami D, Acton D, Giuliani M, Moushey A, Phillips J, Sherwood S, Toll BA, Viswanath K, Warren NJH, Warren GW, Alberg AJ. Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology Journal Of Clinical Oncology 2022, 40: 4144-4155. PMID: 36287017, DOI: 10.1200/jco.22.01749.
Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical OncologyHerbst RS, Hatsukami D, Acton D, Giuliani M, Moushey A, Phillips J, Sherwood S, Toll BA, Viswanath K, Warren NJH, Warren GW, Alberg AJ. Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology Clinical Cancer Research 2022, 28: of1-of10. PMID: 36287033, DOI: 10.1158/1078-0432.ccr-22-2429.
BFAST but be smart: bTMB remains an exploratory biomarker in NSCLCKim SY, Herbst RS. BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC Nature Reviews Clinical Oncology 2022, 20: 3-4. PMID: 36271141, DOI: 10.1038/s41571-022-00698-y.
Cancer of the LungMorgensztern D, Boffa D, Chen A, Dhanasopon A, Goldberg S, Decker R, Devarakonda S, Ko J, Soto L, Waqar S, Wistuba I, Herbst R. Cancer of the Lung 2022, 1-29. DOI: 10.1002/9781119000822.hfcm085.pub2.
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.Shafi S, Aung T, Xirou V, Gavrielatou N, Vathiotis I, Fernandez A, Moutafi M, Yaghoobi V, Herbst R, Liu L, Langermann S, Rimm D. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Laboratory Investigation 2022, 102: 1143-1149. PMID: 36775354, DOI: 10.1038/s41374-022-00796-6.
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)Atkins MB, Abu-Sbeih H, Ascierto PA, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzarella L, Ramalingam SS, Regan MM, Rini BI, Sznol M. Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC) Journal For ImmunoTherapy Of Cancer 2022, 10: e005413. PMID: 36175037, PMCID: PMC9528604, DOI: 10.1136/jitc-2022-005413.
Future Directions in the Management of Non-Small Cell Lung Cancer Harboring Driver Mutations.Herbst RS. Future Directions in the Management of Non-Small Cell Lung Cancer Harboring Driver Mutations. Oncology (Williston Park, N.Y.) 2022, 36: 562-563. PMID: 36107783, DOI: 10.46883/2022.25920974.
P2.12-03 External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized TrialDercle L, Gomez D, Zhao B, Kelly K, Herbst R, Redman M, Gandara D, Schwartz L. P2.12-03 External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial Journal Of Thoracic Oncology 2022, 17: s152. DOI: 10.1016/j.jtho.2022.07.251.
EP14.01-015 IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLCPaz-Ares L, Reck M, Peters S, Borghaei H, Herbst R, Siddiqui M, Cuchelkar V, Bhatt K, Chakrabarti D, Wang L, Morris S, Liu S. EP14.01-015 IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC Journal Of Thoracic Oncology 2022, 17: s532-s533. DOI: 10.1016/j.jtho.2022.07.951.
1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICIReckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Baghdadi T, Hines S, Minichiello K, Gandara D, Kelly K, Herbst R. 1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI Annals Of Oncology 2022, 33: s1033. DOI: 10.1016/j.annonc.2022.07.1173.
LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURATsuboi M, Wu Y, Grohe C, John T, Tarruella M, Wang J, Kato T, Goldman J, Kim S, Yu C, Vu H, Mukhametshina G, Akewanlop C, de Marinis F, Shepherd F, Urban D, Stachowiak M, Bolanos A, Huang X, Herbst R. LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA Annals Of Oncology 2022, 33: s1413-s1414. DOI: 10.1016/j.annonc.2022.08.047.
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancerMoutafi MK, Molero M, Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer Journal For ImmunoTherapy Of Cancer 2022, 10: e004757. PMID: 36002182, PMCID: PMC9413286, DOI: 10.1136/jitc-2022-004757.
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospectsPeters S, Paz-Ares L, Herbst RS, Reck M. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects Journal For ImmunoTherapy Of Cancer 2022, 10: e004863. PMID: 35858709, PMCID: PMC9305809, DOI: 10.1136/jitc-2022-004863.
Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancerHenick BS, Villarroel-Espindola F, Datar I, Sanmamed MF, Yu J, Desai S, Li A, Aguirre-Ducler A, Syrigos K, Rimm DL, Chen L, Herbst RS, Schalper KA. Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer Journal For ImmunoTherapy Of Cancer 2022, 10: e005025. PMID: 35793873, PMCID: PMC9260844, DOI: 10.1136/jitc-2022-005025.
SY01-1 Novel therapies and Immunotherapy for small cell lung cancer: Finally, some progressHerbst R. SY01-1 Novel therapies and Immunotherapy for small cell lung cancer: Finally, some progress Annals Of Oncology 2022, 33: s424. DOI: 10.1016/j.annonc.2022.05.428.
Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLCFernandez AI, Gavrielatou N, McCann L, Shafi S, Moutafi MK, Martinez-Morilla S, Vathiotis IA, Aung TN, Yaghoobi V, Bai Y, Chan YG, Weidler J, Herbst R, Bates M, Rimm DL. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC Journal Of Thoracic Oncology 2022, 17: 1078-1085. PMID: 35764237, DOI: 10.1016/j.jtho.2022.06.007.
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). Clinical Cancer Research 2022, 28: 3752-3760. PMID: 35713632, PMCID: PMC9444942, DOI: 10.1158/1078-0432.ccr-22-0741.
Abstract 1722: Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC)Gregorio M, Nagineni V, Ravi A, Datar I, Mino-Kenudson M, Corredor G, Barrera C, Behlman L, Rimm D, Herbst R, Madabhushi A, Riess J, Velcheti V, Hellmann M, Gainor J, Schalper K. Abstract 1722: Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC) Cancer Research 2022, 82: 1722-1722. DOI: 10.1158/1538-7445.am2022-1722.
Abstract 1974: Immune gene expression signatures associated clinical benefit from nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: An immune biomarker analysis of phase III SWOG LungMAP S1400I trialDuose D, Zhang J, Redman M, Zhang B, Cerami E, Lindsay J, Yu J, Biswas R, Van Nostrand S, Moravec R, Luthra R, Al-Atrash G, Kelly K, Herbst R, Wistuba I, Gettinger S, Bazhenova L, Lee J, Zhang J, Haymaker C. Abstract 1974: Immune gene expression signatures associated clinical benefit from nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: An immune biomarker analysis of phase III SWOG LungMAP S1400I trial Cancer Research 2022, 82: 1974-1974. DOI: 10.1158/1538-7445.am2022-1974.
Abstract 5026: Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancerGonzalez-Kozlova E, Huang H, Redman M, Herbst R, Gettinger S, Bazhenova L, Xie H, Patel M, Nie K, Harris J, Argueta K, Kelly K, Cerami E, Lindsay J, Yu J, Biswas R, Van Nostrand S, Moravec R, Valle D, Kim-schulze S, Gnjatic S. Abstract 5026: Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer Cancer Research 2022, 82: 5026-5026. DOI: 10.1158/1538-7445.am2022-5026.
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunitiesKim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities Nature Reviews Drug Discovery 2022, 21: 529-540. PMID: 35701637, DOI: 10.1038/s41573-022-00493-5.
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800AReckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Neal J, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A Journal Of Clinical Oncology 2022, 40: 2295-2306. PMID: 35658002, PMCID: PMC9287284, DOI: 10.1200/jco.22.00912.
When immunotherapy meets surgery in non-small cell lung cancerHerbst RS, Wang M, Chen L. When immunotherapy meets surgery in non-small cell lung cancer Cancer Cell 2022, 40: 603-605. PMID: 35660136, DOI: 10.1016/j.ccell.2022.05.010.
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancerde Rodas M, Nagineni V, Ravi A, Datar IJ, Mino-Kenudson M, Corredor G, Barrera C, Behlman L, Rimm DL, Herbst RS, Madabhushi A, Riess JW, Velcheti V, Hellmann MD, Gainor J, Schalper KA. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer Journal For ImmunoTherapy Of Cancer 2022, 10: e004440. PMID: 35649657, PMCID: PMC9161072, DOI: 10.1136/jitc-2021-004440.
A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy.Chiang A, Austin M, Stewart T, Arammash M, Bhatt S, Gettinger S, Goldberg S, Wilson F, Newton B, Cohenuram M, Sabbath K, Talsania A, Russo A, Herbst R, Schalper K. A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy. Journal Of Clinical Oncology 2022, 40: 8583-8583. DOI: 10.1200/jco.2022.40.16_suppl.8583.
Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).Vaidya R, Unger J, Qian L, Minichiello K, Herbst R, Gandara D, Neal J, Leal T, Patel J, Dragnev K, Waqar S, Edelman M, Sigal E, Adam S, Malik S, Blanke C, LeBlanc M, Kelly K, Redman M. Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP). Journal Of Clinical Oncology 2022, 40: 6543-6543. DOI: 10.1200/jco.2022.40.16_suppl.6543.
Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.Reckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Al Baghdadi T, Hines S, Qian L, Minichiello K, Gandara D, Kelly K, Herbst R. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. Journal Of Clinical Oncology 2022, 40: 9004-9004. DOI: 10.1200/jco.2022.40.16_suppl.9004.
First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC.Aggarwal C, Haas A, Gordon S, Mehra R, Lee P, Bestvina C, Maldonado F, Velcheti V, Herbst R, Bell S, Gillmor R, Manzanera A, Matheny C, Aguilar-Cordova E, Aguilar L, Barone F, Tak P, Sterman D. First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC. Journal Of Clinical Oncology 2022, 40: 9037-9037. DOI: 10.1200/jco.2022.40.16_suppl.9037.
Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.Gonzalez-Kozlova E, Huang H, Redman M, Herbst R, Gettinger S, Bazhenova L, Xie H, Patel M, Nie K, Harris J, Argueta K, Cerami E, Hong J, Biswas R, Van Nostrand S, Kelly K, Moravec R, Del Valle D, Kim-Schulze S, Gnjatic S. Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab. Journal Of Clinical Oncology 2022, 40: 9044-9044. DOI: 10.1200/jco.2022.40.16_suppl.9044.
Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.Parra E, Duose D, Zhang J, Redman M, Lazcano Segura R, Marques-Piubelli M, Laberiano Fernandez C, Zhang B, Lindsay J, Moravec R, Kannan K, Luthra R, Alatrash G, Herbst R, Wistuba I, Gettinger S, Bazhenova L, Lee J, Zhang J, Haymaker C. Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial. Journal Of Clinical Oncology 2022, 40: 9046-9046. DOI: 10.1200/jco.2022.40.16_suppl.9046.
A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).Skoulidis F, Redman M, Suga J, Al Baghdadi T, Villano J, Goldberg S, Villaruz L, Minichiello K, Gandara D, Herbst R, Kelly K. A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507). Journal Of Clinical Oncology 2022, 40: 9060-9060. DOI: 10.1200/jco.2022.40.16_suppl.9060.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesotheliomaGovindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R, Hellmann MD, Hirsch FR, Johnson ML, Malik S, Morgensztern D, Neal JW, Patel JD, Rimm DL, Sagorsky S, Schwartz LH, Sepesi B, Herbst RS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma Journal For ImmunoTherapy Of Cancer 2022, 10: e003956. PMID: 35640927, PMCID: PMC9157337, DOI: 10.1136/jitc-2021-003956.
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancerShafi S, Aung TN, Xirou V, Gavrielatou N, Vathiotis IA, Fernandez A, Moutafi M, Yaghoobi V, Herbst RS, Liu LN, Langermann S, Rimm DL. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer Laboratory Investigation 2022, 102: 1143-1149. PMID: 35581307, DOI: 10.1038/s41374-022-00796-6.
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial ProfilingMoutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung TN, Yaghoobi V, Fernandez AI, Zugazagoitia J, Herbst R, Schalper KA, Rimm DL. Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling Journal Of Thoracic Oncology 2022, 17: 991-1001. PMID: 35490853, PMCID: PMC9356986, DOI: 10.1016/j.jtho.2022.04.009.
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung CancerHerbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer Journal Of Clinical Oncology 2022, 40: 3383-3393. PMID: 35452273, DOI: 10.1200/jco.22.00227.
Development of an immunohistochemical assay for Siglec-15Shafi S, Aung TN, Robbins C, Zugazagoitia J, Vathiotis I, Gavrielatou N, Yaghoobi V, Fernandez A, Niu S, Liu LN, Cusumano ZT, Leelatian N, Cole K, Wang H, Homer R, Herbst RS, Langermann S, Rimm DL. Development of an immunohistochemical assay for Siglec-15 Laboratory Investigation 2022, 102: 771-778. PMID: 35459795, PMCID: PMC9253057, DOI: 10.1038/s41374-022-00785-9.
Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer—ReplyGettinger S, Redman MW, Herbst RS. Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer—Reply JAMA Oncology 2022, 8: 1-1. PMID: 35142793, DOI: 10.1001/jamaoncol.2021.7790.
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMARemon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, Pignon JP, Besse B, group A, Besse B, Lacas B, Pignon J, Remon J, Berghmans T, Dahlberg S, Felip E, Berghmans T, Besse B, Dahlberg S, Felip E, Garon E, Groen H, Hanna N, Heist R, Herbst R, Heymach J, Lacas B, Adjei A, Heist R, Mandrekar S, Neal J, Okamoto I, Pignon J, Ramlau R, Remon J, Reck M, Scagliotti G, Vansteenkiste J, Yoh K. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA European Journal Of Cancer 2022, 166: 112-125. PMID: 35286903, DOI: 10.1016/j.ejca.2022.02.002.
Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in OncologyJoel MZ, Umrao S, Chang E, Choi R, Yang DX, Duncan JS, Omuro A, Herbst R, Krumholz HM, Aneja S. Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in Oncology JCO Clinical Cancer Informatics 2022, 6: e2100170. PMID: 35271304, PMCID: PMC8932490, DOI: 10.1200/cci.21.00170.
RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.Hunihan L, Zhao D, Lazowski H, Li M, Qian Y, Abriola L, Surovtseva YV, Muthusamy V, Tanoue LT, Rothberg B, Schalper KA, Herbst RS, Wilson FH. RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition. Clinical Cancer Research 2022, 28: 3091-3103. PMID: 35247929, PMCID: PMC9288503, DOI: 10.1158/1078-0432.ccr-21-4291.
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerPassaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn M, Arcila M, Arrieta O, Planchard D, de Marinis F, Dingemans A, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne P, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba I, Wolf J, Wu Y, Yang S, Yang J, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer Annals Of Oncology 2022, 33: 466-487. PMID: 35176458, DOI: 10.1016/j.annonc.2022.02.003.
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMajem M, Goldman JW, John T, Grohe C, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Li S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Atagi S, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst RS, Wu YL. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial Clinical Cancer Research 2022, 28: 2286-2296. PMID: 35012927, PMCID: PMC9359973, DOI: 10.1158/1078-0432.ccr-21-3530.
61P IMpower110: Exploratory analyses of the impact of first-line (1L) atezolizumab on the efficacy of next-line of therapy in PD-L1–selected NSCLCPatel S, Reuss J, Scilla K, Giaccone G, Spigel D, Ngiam C, Zhu Q, Bara I, Ding B, Herbst R. 61P IMpower110: Exploratory analyses of the impact of first-line (1L) atezolizumab on the efficacy of next-line of therapy in PD-L1–selected NSCLC Annals Of Oncology 2021, 32: s1398-s1399. DOI: 10.1016/j.annonc.2021.10.079.
364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking statusGarassino M, Rodriguez-Abreu D, Gadgeel S, Kowalski D, Kasahara K, Felip E, Wu Y, de Castro G, Cho B, Turna H, Horinouchi H, Reck M, Hui R, Garon E, Boyer M, Mok T, Lopes G, Kobie J, Li Y, Ayers M, Cristescu R, Zhao B, Pietanza M, Herbst R. 364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status Journal For ImmunoTherapy Of Cancer 2021, 9: a391-a391. DOI: 10.1136/jitc-2021-sitc2021.364.
457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC)Gutierrez M, Lam W, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Finocchiaro G, Ahn M, Luft A, Landers G, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst R. 457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC) Journal For ImmunoTherapy Of Cancer 2021, 9: a485-a485. DOI: 10.1136/jitc-2021-sitc2021.457.
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCWu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, Kato T, Laktionov K, Vu HV, Wang Z, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Atasoy A, Herbst RS, Tsuboi M. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC Journal Of Thoracic Oncology 2021, 17: 423-433. PMID: 34740861, DOI: 10.1016/j.jtho.2021.10.014.
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerWu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer Future Oncology 2021, 17: 4827-4835. PMID: 34723634, DOI: 10.2217/fon-2021-0752.
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLCHirsch FR, Redman MW, Moon J, Agustoni F, Herbst RS, Semrad TJ, Varella-Garcia M, Rivard CJ, Kelly K, Gandara DR, Mack PC. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC Clinical Lung Cancer 2021, 23: 60-71. PMID: 34753703, PMCID: PMC8766941, DOI: 10.1016/j.cllc.2021.10.002.
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung CancerGettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer JAMA Oncology 2021, 7: 1368-1377. PMID: 34264316, PMCID: PMC8283667, DOI: 10.1001/jamaoncol.2021.2209.
LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLCMartinez-Marti A, Majem M, Barlesi F, Costa E, Chu Q, Monnet I, Sanchez A, Dahkil S, Camidge D, He P, Soo-Hoo Y, Cooper Z, Kumar R, Bothos J, Aggarwal C, Herbst R. LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC Annals Of Oncology 2021, 32: s1320. DOI: 10.1016/j.annonc.2021.08.2121.
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy SC, Crawford J, Bradley JD, Stinchcombe TE, Ramalingam SS, Miao J, Minichiello K, Herbst RS, Papadimitrakopoulou VA, Kelly K, Gandara DR. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) Journal For ImmunoTherapy Of Cancer 2021, 9: e002973. PMID: 34429332, PMCID: PMC8386207, DOI: 10.1136/jitc-2021-002973.
Toward personalized treatment approaches for non-small-cell lung cancerWang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer Nature Medicine 2021, 27: 1345-1356. PMID: 34385702, DOI: 10.1038/s41591-021-01450-2.
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLCJassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, Mocci S, Enquist I, Komatsubara K, McCleland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst RS. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC Journal Of Thoracic Oncology 2021, 16: 1872-1882. PMID: 34265434, DOI: 10.1016/j.jtho.2021.06.019.
A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 ExpressionHerbst R, Jassem J, Abogunrin S, James D, McCool R, Belleli R, Giaccone G, De Marinis F. A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression Frontiers In Oncology 2021, 11: 676732. PMID: 34307144, PMCID: PMC8300186, DOI: 10.3389/fonc.2021.676732.
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042Mansfield AS, Herbst RS, de Castro G, Hui R, Peled N, Kim DW, Novello S, Satouchi M, Wu YL, Garon EB, Reck M, Robinson AG, Samkari A, Piperdi B, Ebiana V, Lin J, Mok TSK. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 JTO Clinical And Research Reports 2021, 2: 100205. PMID: 34590048, PMCID: PMC8474394, DOI: 10.1016/j.jtocrr.2021.100205.
Abstract LB197: An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistanceArniella M, Ravi A, Gainor J, Stewart C, Freeman S, Awad M, Forde P, Anagnostou V, Henick B, Riess J, Gibbons D, Pennell N, Velcheti V, Leshchiner I, Kim J, Digumarthy S, Mino-Kenudson M, Heymach J, Hacohen N, Rizvi N, Herbst R, Velculescu V, Brahmer J, Schalper K, Jänne P, Wolchok J, Shaw A, Getz G, Hellman M. Abstract LB197: An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance Cancer Research 2021, 81: lb197-lb197. DOI: 10.1158/1538-7445.am2021-lb197.
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLCGrant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC Nature Reviews Clinical Oncology 2021, 18: 625-644. PMID: 34168333, DOI: 10.1038/s41571-021-00520-1.
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLCHerbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, Han JY, Majem M, Forster MD, Monnet I, Novello S, Gubens MA, Boyer M, Su WC, Samkari A, Jensen EH, Kobie J, Piperdi B, Baas P. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC Journal Of Thoracic Oncology 2021, 16: 1718-1732. PMID: 34048946, DOI: 10.1016/j.jtho.2021.05.001.
A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).Riess J, Redman M, Wheatley-Price P, Faller B, Villaruz L, Corum L, Gowda A, Srkalovic G, Osarogiagbon R, Baumgart M, Qian L, Minichiello K, Gandara D, Herbst R, Kelly K. A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A). Journal Of Clinical Oncology 2021, 39: 9024-9024. DOI: 10.1200/jco.2021.39.15_suppl.9024.
Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).Reckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Baghdadi T, Hines S, Qian L, Minichiello K, Gandara D, Herbst R, Kelly K. Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A). Journal Of Clinical Oncology 2021, 39: 9075-9075. DOI: 10.1200/jco.2021.39.15_suppl.9075.
Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN).Roth JA, Trivedi MS, Gray SW, Patrick DL, Delaney DM, Watabayashi K, Litwin P, Shah P, Crew KD, Yee M, Redman MW, Unger JM, Papadimitrakopoulou V, Johnson J, Kelly K, Gandara D, Herbst RS, Hershman DL, Ramsey SD. Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO Oncology Practice 2021, 17: e1821-e1829. PMID: 33797955, PMCID: PMC9810137, DOI: 10.1200/op.20.00770.
How a Priority of Community Outreach and Engagement Is Changing Health Equity at Cancer CentersJacobsen PB, Baskin ML, Chen MS, Herbst RS, Lathan CS. How a Priority of Community Outreach and Engagement Is Changing Health Equity at Cancer Centers Health Equity 2021, 5: 227-235. PMID: 33937609, PMCID: PMC8086529, DOI: 10.1089/heq.2021.29005.rtd.
Postoperativer Chemotherapie-Einsatz und Ergebnisse der ADAURA-Studie: Osimertinib als adjuvante Therapie beim resezierten EGFR-mutierten NSCLCGrohé C, Wu Y, John T, Majem M, Goldman J, Kim S, Kato T, Laktionov K, Vu H, Wang Z, Lu S, Lee K, Akewanlop C, Yu C, De Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Atasoy A, Herbst R, Tsuboi M, Engel-Riedel W. Postoperativer Chemotherapie-Einsatz und Ergebnisse der ADAURA-Studie: Osimertinib als adjuvante Therapie beim resezierten EGFR-mutierten NSCLC Pneumologie 2021, 75: s18-s19. DOI: 10.1055/s-0041-1723297.
Patientenberichte aus ADAURA: HRQol Daten zu Osimertinib als adjuvante Therapie bei Patienten mit reseziertem EGFR-mutiertem (EGFRm) NSCLCEngel-Riedel W, Majem M, Goldman J, Grohé C, John T, Laktionov K, Kim S, Kato T, Vu H, Lu S, Lee K, Akewanlop C, Yu C, de Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst R, Wu Y, Wohlleber M. Patientenberichte aus ADAURA: HRQol Daten zu Osimertinib als adjuvante Therapie bei Patienten mit reseziertem EGFR-mutiertem (EGFRm) NSCLC Pneumologie 2021, 75: s21-s21. DOI: 10.1055/s-0041-1723302.
Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infectionMcPadden J, Warner F, Young HP, Hurley NC, Pulk RA, Singh A, Durant TJS, Gong G, Desai N, Haimovich A, Taylor RA, Gunel M, Dela Cruz CS, Farhadian SF, Siner J, Villanueva M, Churchwell K, Hsiao A, Torre CJ, Velazquez EJ, Herbst RS, Iwasaki A, Ko AI, Mortazavi BJ, Krumholz HM, Schulz WL. Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection PLOS ONE 2021, 16: e0243291. PMID: 33788846, PMCID: PMC8011821, DOI: 10.1371/journal.pone.0243291.
A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer ImmunotherapySanmamed MF, Nie X, Desai SS, Villaroel-Espindola F, Badri T, Zhao D, Kim AW, Ji L, Zhang T, Quinlan E, Cheng X, Han X, Vesely MD, Nassar AF, Sun J, Zhang Y, Kim TK, Wang J, Melero I, Herbst RS, Schalper KA, Chen L. A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy Cancer Discovery 2021, 11: 1700-1715. PMID: 33658301, PMCID: PMC9421941, DOI: 10.1158/2159-8290.cd-20-0962.
P09.55 A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung CancerWalia G, Lu M, Bourla A, Santos E, Schulze K, Cabili M, Williams E, Mirkovic N, Dicecca R, Lee S, Fang B, Schwartzberg L, Herbst R, Chiang A. P09.55 A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung Cancer Journal Of Thoracic Oncology 2021, 16: s316-s317. DOI: 10.1016/j.jtho.2021.01.483.
Abstract PO-074: The impact of phenotypic bias in the generalizability of deep learning models in non-small cell lung cancerGilson A, Du J, Janda G, Umrao S, Joel M, Choi R, Herbst R, Krumholz H, Aneja S. Abstract PO-074: The impact of phenotypic bias in the generalizability of deep learning models in non-small cell lung cancer Clinical Cancer Research 2021, 27: po-074-po-074. DOI: 10.1158/1557-3265.adi21-po-074.
Abstract PO-078: Exploring adversarial image attacks on deep learning models in oncologyJoel M, Umrao S, Chang E, Choi R, Yang D, Gilson A, Herbst R, Krumholz H, Aneja S. Abstract PO-078: Exploring adversarial image attacks on deep learning models in oncology Clinical Cancer Research 2021, 27: po-078-po-078. DOI: 10.1158/1557-3265.adi21-po-078.
OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLCWu Y, John T, Grohe C, Majem M, Goldman J, Kim S, Kato T, Laktionov K, Vu H, Wang Z, Lu S, Lee K, Akewanlop C, Yu C, De Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Atasoy A, Herbst R, Tsuboi M. OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC Journal Of Thoracic Oncology 2021, 16: s113-s114. DOI: 10.1016/j.jtho.2021.01.292.
P01.21 ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI EraRemon J, Lacas B, Herbst R, Reck M, Garon E, Scagliotti G, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen H, Heymach J, Mandrekar S, Okamoto I, Neal J, Heist R, Pignon J, Besse B. P01.21 ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era Journal Of Thoracic Oncology 2021, 16: s244-s245. DOI: 10.1016/j.jtho.2021.01.345.
FP13.01 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLCHerbst R, Garon E, Kim D, Cho B, Gervais R, Perez-Gracia J, Han J, Majem M, Forster M, Monnet I, Novello S, Gubens M, Boyer M, Su W, Samkari A, Jensen E, Piperdi B, Baas P. FP13.01 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC Journal Of Thoracic Oncology 2021, 16: s223-s224. DOI: 10.1016/j.jtho.2021.01.140.
OA01.04 Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400AHirsch F, Hua X, Wu M, Neal J, Cheng H, Gettinger S, Bazhenova L, Papadimitrakopoulou V, Borghaei H, Mack P, Kelly K, Herbst R, Gandara D, Redman M, Kozono D. OA01.04 Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A Journal Of Thoracic Oncology 2021, 16: s102. DOI: 10.1016/j.jtho.2021.01.273.
MA08.10 LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular AnalysisMack P, Minichielle K, Redman M, Tolba K, Kozono D, Waqar S, Chowdhury A, Dowlati A, Neal J, Dragnev K, Aggarwal C, Hirsch F, Kelly K, Gandara D, Herbst R. MA08.10 LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis Journal Of Thoracic Oncology 2021, 16: s163-s164. DOI: 10.1016/j.jtho.2021.01.196.
MA11.10 Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400)Kozono D, Hua X, Wu M, Tolba K, Waqar S, Dragnev K, Cheng H, Hirsch F, Mack P, Kelly K, Herbst R, Gandara D, Redman M. MA11.10 Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400) Journal Of Thoracic Oncology 2021, 16: s176-s177. DOI: 10.1016/j.jtho.2021.01.254.
OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLCMajem M, Goldman J, John T, Grohe C, Laktionov K, Kim S, Kato T, Vu H, Lu S, Lee K, Akewanlop C, Yu C, De Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst R, Wu Y. OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC Journal Of Thoracic Oncology 2021, 16: s112-s113. DOI: 10.1016/j.jtho.2021.01.291.
FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLCHerbst R, De Marinis F, Giaccone G, Vergnenegre A, Barrios C, Morise M, Felip E, Oprean C, Kim Y, Andric Z, Mocci S, Enquist I, Komatsubara K, Mccleland M, Deng Y, Kuriki H, Villalobos M, Phan S, Spigel D, Jassem J. FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC Journal Of Thoracic Oncology 2021, 16: s224-s225. DOI: 10.1016/j.jtho.2021.01.142.
Osimertinib in EGFR-Mutated Lung Cancer. Reply.Herbst RS, Wu YL, Tsuboi M. Osimertinib in EGFR-Mutated Lung Cancer. Reply. New England Journal Of Medicine 2021, 384: 675-676. PMID: 33596365, DOI: 10.1056/nejmc2033951.
Atezolizumab for PD-L1-Selected Patients with NSCLC. Reply.Herbst RS, Kuriki H, Spigel DR. Atezolizumab for PD-L1-Selected Patients with NSCLC. Reply. New England Journal Of Medicine 2021, 384: 584-585. PMID: 33567202, DOI: 10.1056/nejmc2032432.
Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeonsJones DR, Wu YL, Tsuboi M, Herbst RS. Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons Journal Of Thoracic And Cardiovascular Surgery 2021, 162: 288-292. PMID: 33691940, PMCID: PMC8519337, DOI: 10.1016/j.jtcvs.2021.02.008.
Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET FusionsHerbst RS, Aisner DL, Sonett JR, Turk AT, Weintraub JL, Lindeman NI. Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions Frontiers In Medicine 2021, 7: 562480. PMID: 33553195, PMCID: PMC7859651, DOI: 10.3389/fmed.2020.562480.
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400GOwonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G Clinical Lung Cancer 2021, 22: 187-194.e1. PMID: 33583720, PMCID: PMC8637652, DOI: 10.1016/j.cllc.2021.01.001.
Clearing the Haze: What Do We Still Need to Learn about Electronic Nicotine Delivery Systems?Fucito LM, Malinosky H, Baldassarri SR, Herbst RS. Clearing the Haze: What Do We Still Need to Learn about Electronic Nicotine Delivery Systems? Cancer Prevention Research 2021, 14: 5-10. PMID: 33148678, PMCID: PMC8324047, DOI: 10.1158/1940-6207.capr-20-0394.
SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)Borghaei H, Redman MW, Kelly K, Waqar SN, Robert F, Kiefer GJ, Stella PJ, Minichiello K, Gandara DR, Herbst RS, Papadimitrakopoulou VA. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study) Clinical Lung Cancer 2020, 22: 178-186. PMID: 33358401, PMCID: PMC8686189, DOI: 10.1016/j.cllc.2020.10.015.
Clinical Characteristics and Outcomes for 7,995 Patients with SARS-CoV-2 Infection.McPadden J, Warner F, Young HP, Hurley NC, Pulk RA, Singh A, Durant TJ, Gong G, Desai N, Haimovich A, Taylor RA, Gunel M, Dela Cruz CS, Farhadian SF, Siner J, Villanueva M, Churchwell K, Hsiao A, Torre CJ, Velazquez EJ, Herbst RS, Iwasaki A, Ko AI, Mortazavi BJ, Krumholz HM, Schulz WL. Clinical Characteristics and Outcomes for 7,995 Patients with SARS-CoV-2 Infection. MedRxiv : The Preprint Server For Health Sciences 2020 PMID: 32743602, PMCID: PMC7386526, DOI: 10.1101/2020.07.19.20157305.
Introduction by the Guest Editors.Goldberg SB, Herbst RS. Introduction by the Guest Editors. Cancer Journal (Sudbury, Mass.) 2020, 26: 471-472. PMID: 33298717, DOI: 10.1097/PPO.0000000000000487.
356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrenceTsuboi M, Wu Y, He J, John T, Grohe C, Majem M, Goldman J, Laktionov K, Kim S, Kato T, Vu H, Akewanlop C, Yu C, de Marinis F, Domine M, Shepherd F, Yan C, Atasoy A, Herbst R. 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence Annals Of Oncology 2020, 31: s1378. DOI: 10.1016/j.annonc.2020.10.349.
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocolRedman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol The Lancet Oncology 2020, 21: 1589-1601. PMID: 33125909, PMCID: PMC8109255, DOI: 10.1016/s1470-2045(20)30475-7.
The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trialsTam AL, Papadimitrakopoulou V, Wistuba II, Lee JJ, Ensor JE, Kim ES, Kalhor N, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks ME, Hong WK, Gupta S. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials Clinical Radiology 2020, 76: 155.e25-155.e34. PMID: 33268083, DOI: 10.1016/j.crad.2020.09.024.
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLCHerbst RS, Arkenau HT, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Mi G, Wang H, Rasmussen E, Ferry D, Chao BH, Paz-Ares L. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC Journal Of Thoracic Oncology 2020, 16: 289-298. PMID: 33068794, DOI: 10.1016/j.jtho.2020.10.004.
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF TrialChau I, Penel N, Soriano AO, Arkenau HT, Cultrera J, Santana-Davila R, Calvo E, Le Tourneau C, Zender L, Bendell JC, Mi G, Gao L, McNeely SC, Oliveira JM, Ferry D, Herbst RS, Fuchs CS. Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial Cancers 2020, 12: 2985. PMID: 33076423, PMCID: PMC7602637, DOI: 10.3390/cancers12102985.
A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753) Clinical Lung Cancer 2020, 22: 170-177. PMID: 33221175, PMCID: PMC8044254, DOI: 10.1016/j.cllc.2020.09.013.
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, Gandara DR. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. Journal Of Clinical Oncology 2020, 38: 4076-4085. PMID: 33021871, PMCID: PMC7768342, DOI: 10.1200/jco.20.01149.
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLCHerbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC New England Journal Of Medicine 2020, 383: 1328-1339. PMID: 32997907, DOI: 10.1056/nejmoa1917346.
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung CancerWu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer New England Journal Of Medicine 2020, 383: 1711-1723. PMID: 32955177, DOI: 10.1056/nejmoa2027071.
Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrenceTsuboi M, Wu Y, He J, John T, Grohe C, Majem M, Goldman J, Laktionov K, Kim S, Kato T, Vu H, Akewanlop C, Yu C, de Marinis F, Domine M, Shepherd F, Yan C, Atasoy A, Herbst R. Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence Annals Of Oncology 2020, 31: s1177. DOI: 10.1016/j.annonc.2020.08.2279.
Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLCNishio M, Peled N, Zer A, Houghton B, Bar J, Drew D, Herbst R, Rodriguez-Abreu D, Talpur R, Golden L, Yin L, Dang T, Hui R. Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC Annals Of Oncology 2020, 31: s848-s849. DOI: 10.1016/j.annonc.2020.08.1627.
Abstract 2002: Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLCLiu Y, Zugazagoitia J, Schalper K, Herbst R, Rimm D. Abstract 2002: Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLC Cancer Research 2020, 80: 2002-2002. DOI: 10.1158/1538-7445.am2020-2002.
Abstract 5525: VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancerDing A, Villarroel-Espindola F, Ducler A, Henick B, Desai S, Gianino N, Zugazagoitia J, Rimm D, Robert A, Cruzalegui F, Ferré P, Herbst R, Sanmamed M, Chen L, Schalper K. Abstract 5525: VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancer Cancer Research 2020, 80: 5525-5525. DOI: 10.1158/1538-7445.am2020-5525.
Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial ProfilingZugazagoitia J, Gupta S, Liu Y, Fuhrman K, Gettinger S, Herbst RS, Schalper KA, Rimm DL. Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling Clinical Cancer Research 2020, 26: 4360-4368. PMID: 32253229, PMCID: PMC7442721, DOI: 10.1158/1078-0432.ccr-20-0175.
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical PracticeEguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu B, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice Clinical Cancer Research 2020, 26: 4186-4197. PMID: 32354698, DOI: 10.1158/1078-0432.ccr-20-0798.
Longitudinal analyses reveal immunological misfiring in severe COVID-19Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A, Mohanty S, Wang H, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Muenker MC, Fournier JB, Campbell M, Odio CD, Casanovas-Massana A, Herbst R, Shaw A, Medzhitov R, Schulz W, Grubaugh N, Dela Cruz C, Farhadian S, Ko A, Omer S, Iwasaki A. Longitudinal analyses reveal immunological misfiring in severe COVID-19 Nature 2020, 584: 463-469. PMID: 32717743, PMCID: PMC7477538, DOI: 10.1038/s41586-020-2588-y.
Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non–small-cell lung carcinomaBoulle G, Velut Y, Mansuet-Lupo A, Gibault L, Blons H, Fournel L, Boni A, Cremer I, Wislez M, Duchatelle V, Trédaniel J, Hammond S, Herbst R, Alifano M, Giraud P, Damotte D. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non–small-cell lung carcinoma European Journal Of Cancer 2020, 135: 221-229. PMID: 32610210, DOI: 10.1016/j.ejca.2020.04.040.
Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.Herbst R, Tsuboi M, John T, Grohé C, Majem M, Goldman J, Kim S, Marmol D, Rukazenkov Y, Wu Y. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. Journal Of Clinical Oncology 2020, 38: lba5-lba5. DOI: 10.1200/jco.2020.38.18_suppl.lba5.
Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.Mack P, Redman M, Moon J, Goldberg S, Herbst R, Melnick M, Walther Z, Hirsch F, Politi K, Kelly K, Gandara D. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. Journal Of Clinical Oncology 2020, 38: 9532-9532. DOI: 10.1200/jco.2020.38.15_suppl.9532.
A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.Lu M, Walia G, Schulze K, Doral M, Maund S, Gaffey S, Cabili M, Bourla A, Green R, Santos E, Herbst R, Chiang A, Schwartzberg L. A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. Journal Of Clinical Oncology 2020, 38: tps2087-tps2087. DOI: 10.1200/jco.2020.38.15_suppl.tps2087.
Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.Herbst R, Arkenau H, Calvo E, Bendell J, Penel N, Fuchs C, McNeely S, Rasmussen E, Wang H, Oliveira J, Ferry D, Chau I. Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF. Journal Of Clinical Oncology 2020, 38: 3089-3089. DOI: 10.1200/jco.2020.38.15_suppl.3089.
Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial.Killian J, Wright C, Chan L, Danziger N, Elvin J, Vergilio J, Lin D, Williams E, Ramkissoon S, Severson E, Hemmerich A, Duncan D, Edgerly C, Tse J, McGregor K, Schrock A, Alexander B, Ross J, Redman M, Herbst R. Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial. Journal Of Clinical Oncology 2020, 38: 3622-3622. DOI: 10.1200/jco.2020.38.15_suppl.3622.
NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting.Adelson K, Herbst R, Peterson P, Ingram M, Oliver B, Agrawal T, Davies M, Rudell E. NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting. Journal Of Clinical Oncology 2020, 38: 7054-7054. DOI: 10.1200/jco.2020.38.15_suppl.7054.
Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).Redman M, Papadimitrakopoulou V, Minichiello K, Gandara D, Hirsch F, Mack P, Schwartz L, Vokes E, Ramalingam S, Leighl N, Bradley J, LeBlanc M, Malik S, Miller V, Sigal E, Adam S, Blanke C, Kelly K, Herbst R. Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). Journal Of Clinical Oncology 2020, 38: 9576-9576. DOI: 10.1200/jco.2020.38.15_suppl.9576.
Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.de Marinis F, Giaccone G, Herbst R, Oprean C, Szczesna A, Boukovinas I, Bonomi L, Kim Y, Summers Y, Kurata T, Komatsubara K, Chen M, Deng Y, Kuriki H, Mocci S, Phan S, Jassem J, Spigel D. Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC. Journal Of Clinical Oncology 2020, 38: 9594-9594. DOI: 10.1200/jco.2020.38.15_suppl.9594.
SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).Leighl N, Redman M, Rizvi N, Hirsch F, Mack P, Schwartz L, Wade J, Irvin W, Reddy S, Crawford J, Bradley J, Stinchcombe T, Ramalingam S, Miao J, Minichiello K, Gandara D, Herbst R, Papadimitrakopoulou V, Kelly K. SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study). Journal Of Clinical Oncology 2020, 38: 9623-9623. DOI: 10.1200/jco.2020.38.15_suppl.9623.
IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC).Jassem J, Herbst R, de Marinis F, Cadranel J, Csőszi T, Isla D, Chen G, Syrigos K, Cortinovis D, Hida T, Mocci S, Phan S, Enquist I, Patel H, Villalobos M, Wen X, Deng Y, Kuriki H, Spigel D, Giaccone G. IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2020, 38: e21623-e21623. DOI: 10.1200/jco.2020.38.15_suppl.e21623.
O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLCHerbst R, De Marinis F, Giaccone G, Reinmuth N, Vergnenegre A, Barrios C, Morise M, Font E, Andric Z, Geater S, Ozguroglu M, Mocci S, McCleland M, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, Jassem J, Spigel D. O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC Journal For ImmunoTherapy Of Cancer 2020, 8: a1. DOI: 10.1136/lba2019.1.
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trialGoldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.
Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendationsRemon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV. Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations Journal Of Thoracic Oncology 2020, 15: 914-947. PMID: 32179179, DOI: 10.1016/j.jtho.2020.03.006.
Frequenz von EGFR (epidermaler Wachstumsfaktorrezeptor)-Mutationen im Stadium IB-IIIA NSCLC nach kompletter TumorresektionRittmeyer A, Tsuboi M, Herbst R, John T, Majem M, Goldman J, Kim S, Yu C, Miziara J, Novello S, Urban D, Akewanlop C, Öztürk A, Quang B, Kowalski D, Marmol D, Marotti M, Laus G, Wu Y, Engel-Riedel W. Frequenz von EGFR (epidermaler Wachstumsfaktorrezeptor)-Mutationen im Stadium IB-IIIA NSCLC nach kompletter Tumorresektion Pneumologie 2020, 74: 131-131. DOI: 10.1055/s-0039-3403361.
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, Arvis CD, Majem M, Forster MD, Monnet I, Novello S, Szalai Z, Gubens MA, Su WC, Ceresoli GL, Samkari A, Jensen EH, Lubiniecki GM, Baas P. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal Of Clinical Oncology 2020, 38: 1580-1590. PMID: 32078391, DOI: 10.1200/jco.19.02446.
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade TherapyLiu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger S, Herbst RS, Schalper KA, Rimm DL. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy Clinical Cancer Research 2020, 26: 970-977. PMID: 31615933, PMCID: PMC7024671, DOI: 10.1158/1078-0432.ccr-19-1040.
Comprehensive T cell repertoire characterization of non-small cell lung cancerReuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer Nature Communications 2020, 11: 603. PMID: 32001676, PMCID: PMC6992630, DOI: 10.1038/s41467-019-14273-0.
Frontline immunotherapy for NSCLC — the tale of the tailChiang AC, Herbst RS. Frontline immunotherapy for NSCLC — the tale of the tail Nature Reviews Clinical Oncology 2020, 17: 73-74. PMID: 31907372, DOI: 10.1038/s41571-019-0317-y.
LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 studyHerbst R, de Marinis F, Giaccone G, Reinmuth N, Vergnenegre A, Barrios C, Morise M, Felip E, Andric Z, Geater S, Ozguroglu M, Mocci S, McCleland M, Zou W, Enquist I, Komatsubara K, Deng Y, Kuriki H, Spigel D, Jassem J. LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study Annals Of Oncology 2019, 30: xi62-xi63. DOI: 10.1093/annonc/mdz453.
LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042Herbst R, Lopes G, Kowalski D, Kasahara K, Wu Y, De Castro G, Cho B, Turna H, Cristescu R, Aurora-Garg D, Lunceford J, Kobie J, Ayers M, Pietanza M, Piperdi B, Mok T. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 Annals Of Oncology 2019, 30: xi63-xi64. DOI: 10.1093/annonc/mdz453.001.
Small molecule combats cancer-causing KRAS protein at lastHerbst RS, Schlessinger J. Small molecule combats cancer-causing KRAS protein at last Nature 2019, 575: 294-295. PMID: 31705127, DOI: 10.1038/d41586-019-03242-8.
Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non–Small Cell Lung CancerZugazagoitia J, Liu Y, Toki M, McGuire J, Ahmed FS, Henick BS, Gupta R, Gettinger S, Herbst R, Schalper KA, Rimm DL. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non–Small Cell Lung Cancer Journal Of Thoracic Oncology 2019, 14: 2084-2096. PMID: 31605795, PMCID: PMC6951804, DOI: 10.1016/j.jtho.2019.09.014.
LBA78 IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLCSpigel D, de Marinis F, Giaccone G, Reinmuth N, Vergnenegre A, Barrios C, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Mocci S, McCleland M, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, Jassem J, Herbst R. LBA78 IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC Annals Of Oncology 2019, 30: v915. DOI: 10.1093/annonc/mdz293.
1589TiP KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC)Gutierrez M, Lam W, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. 1589TiP KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC) Annals Of Oncology 2019, 30: v656. DOI: 10.1093/annonc/mdz260.111.
1450P Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resectionTsuboi M, Herbst R, John T, Grohe C, Majem M, Goldman J, Kim S, Yu C, Miziara J, Novello S, Urban D, Akewanlop C, Öztürk A, Quang B, Kowalski D, Marmol D, Marotti M, Laus G, Wu Y. 1450P Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection Annals Of Oncology 2019, 30: v589. DOI: 10.1093/annonc/mdz258.010.
1482O Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042Mansfield A, Herbst R, Castro G, Hui R, Peled N, Kim D, Novello S, Satouchi M, Wu Y, Garon E, Reck M, Robinson A, Samkari A, Piperdi B, Ebiana V, Lin J, Mok T. 1482O Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042 Annals Of Oncology 2019, 30: v604-v606. DOI: 10.1093/annonc/mdz260.004.
LBA79 Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trialsHerbst R, Lopes G, Kowalski D, Nishio M, Wu Y, de Castro G, Baas P, Kim D, Gubens M, Cristescu R, Aurora-Garg D, Albright A, Ayers M, Loboda A, Lunceford J, Kobie J, Lubiniecki G, Pietanza M, Piperdi B, Mok T. LBA79 Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials Annals Of Oncology 2019, 30: v916-v917. DOI: 10.1093/annonc/mdz394.077.
SY6-1 Cancer immunotherapy; A paradigm shift in the first-line treatment of lung cancerHerbst R. SY6-1 Cancer immunotherapy; A paradigm shift in the first-line treatment of lung cancer Annals Of Oncology 2019, 30: vi32. DOI: 10.1093/annonc/mdz325.
P1.01-107 KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non–Small Cell Lung CancerGutierrez M, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Lam W, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. P1.01-107 KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer Journal Of Thoracic Oncology 2019, 14: s403. DOI: 10.1016/j.jtho.2019.08.822.
OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung CancerBazhenova L, Redman M, Gettinger S, Hirsch F, Mack P, Schwartz L, Gandara D, Bradley J, Stinchcombe T, Leighl N, Ramalingam S, Tavernier S, Minichiello K, Kelly K, Papadimitrakopoulou V, Herbst R. OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer Journal Of Thoracic Oncology 2019, 14: s214. DOI: 10.1016/j.jtho.2019.08.423.
P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung CancerHerbst R, Barlesi F, Paz-Ares L, Raben D, Aggarwal C, Bothos J, Samadani R, He P, Angra N, Martinez P. P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer Journal Of Thoracic Oncology 2019, 14: s450-s451. DOI: 10.1016/j.jtho.2019.08.931.
MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung CancerReuben A, Zhang J, Gittelman R, Chiou S, Li J, Fujimoto J, Behrens C, Kheradmand F, Chow C, Bernatchez C, Eterovic A, Benzeno S, Vignali M, Wu X, Ye Y, Cascone T, Herbst R, Swisher S, Kadara H, Moran C, Zhang J, Scheet P, Vaporciyan A, Sepesi B, Gibbons D, Robins H, Hwu P, Heymach J, Sharma P, Allison J, Lee J, Davis M, Wistuba I, Futreal P, Zhang J. MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer Journal Of Thoracic Oncology 2019, 14: s293. DOI: 10.1016/j.jtho.2019.08.589.
MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF)Herbst R, Arkenau H, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Chao B, Ferry D, Mi G, Paz-Ares L. MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF) Journal Of Thoracic Oncology 2019, 14: s307. DOI: 10.1016/j.jtho.2019.08.615.
ES06.01 Recent Advances in Second Line TreatmentHerbst R. ES06.01 Recent Advances in Second Line Treatment Journal Of Thoracic Oncology 2019, 14: s27. DOI: 10.1016/j.jtho.2019.08.092.
MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLCSkoulidis F, Arbour K, Hellmann M, Patil P, Marmarelis M, Owen D, Awad M, Murray J, Levy B, Hellyer J, Gainor J, Stewart T, Goldberg S, Dimou A, Bestvina C, Cummings A, Elamin Y, Lam V, Zhang J, Shu C, Riess J, Blakely C, Pecot C, Mezquita L, Tabbò F, Sacher A, Scheffler M, Ricciuti B, Venkatraman D, Rizvi H, Liu C, Johnston R, Ni Y, Azok J, Kier M, Katz S, Davies K, Segal J, Ritterhouse L, Shaish H, Lacroix L, Memmott R, Madrigal J, Goldman J, Lau S, Killam J, Walther Z, Carter B, Woodcock M, Roth J, Swisher S, Leighl N, Digumarthy S, Mooradian M, Rotow J, Wolf J, Scagliotti G, Planchard D, Besse B, Bivona T, Gandara D, Garon E, Rizvi N, Camidge D, Schalper K, Herbst R, Shaw A, Neal J, Wakelee H, Brahmer J, Jänne P, Carbone D, Aggarwal C, Pennell N, Rudin C, Papadimitrakopoulou V, Heymach J. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC Journal Of Thoracic Oncology 2019, 14: s294-s295. DOI: 10.1016/j.jtho.2019.08.591.
Immunotherapy in Non–Small Cell Lung Cancer: Facts and HopesDoroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes Clinical Cancer Research 2019, 25: 4592-4602. PMID: 30824587, PMCID: PMC6679805, DOI: 10.1158/1078-0432.ccr-18-1538.
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell AnalysisDatar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías L, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis Clinical Cancer Research 2019, 25: 4663-4673. PMID: 31053602, PMCID: PMC7444693, DOI: 10.1158/1078-0432.ccr-18-4142.
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T CellsDong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, Park JJ, Kim HR, Errami Y, Guzman CD, Zhou X, Chen KY, Renauer PA, Du Y, Shen J, Lam SZ, Zhou JJ, Lannin DR, Herbst RS, Chen S. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells Cell 2019, 178: 1189-1204.e23. PMID: 31442407, PMCID: PMC6719679, DOI: 10.1016/j.cell.2019.07.044.
Challenges and approaches to implementing master/basket trials in oncologyBurd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR. Challenges and approaches to implementing master/basket trials in oncology Blood Advances 2019, 3: 2237-2243. PMID: 31337605, PMCID: PMC6650731, DOI: 10.1182/bloodadvances.2019031229.
SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration–Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration–Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) Journal Of Thoracic Oncology 2019, 14: 1853-1859. PMID: 31302234, PMCID: PMC6764876, DOI: 10.1016/j.jtho.2019.06.027.
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trialHerbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial The Lancet Oncology 2019, 20: 1109-1123. PMID: 31301962, DOI: 10.1016/s1470-2045(19)30458-9.
Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytesToki M, Zugazagoitia J, Altan M, Liu L, Mani N, Liu Y, Syrigos K, Chen L, Langermann S, Herbst R, Rimm D. Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes 2019, 3151-3151. DOI: 10.1158/1538-7445.sabcs18-3151.
Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancerGutierrez M, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer 2019, ct227-ct227. DOI: 10.1158/1538-7445.sabcs18-ct227.
SO-002 Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)Chau I, Bendell J, Soriano A, Arkenau H, Cultrera J, Santana-Davila R, Calvo E, Le Tourneau C, Zender L, Mi G, Schelman W, Ferry D, Herbst R, Fuchs C. SO-002 Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF) Annals Of Oncology 2019, 30: iv122. DOI: 10.1093/annonc/mdz157.001.
Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytesToki M, Zugazagoitia J, Altan M, Liu L, Mani N, Liu Y, Syrigos K, Chen L, Langermann S, Herbst R, Rimm D. Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes Cancer Research 2019, 79: 3151-3151. DOI: 10.1158/1538-7445.am2019-3151.
Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancerGutierrez M, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer Cancer Research 2019, 79: ct227-ct227. DOI: 10.1158/1538-7445.am2019-ct227.
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)Aggarwal C, Redman MW, Lara PN, Borghaei H, Hoffman P, Bradley JD, Newman AJ, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) Journal Of Thoracic Oncology 2019, 14: 1847-1852. PMID: 31195180, PMCID: PMC6901020, DOI: 10.1016/j.jtho.2019.05.041.
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)Langer CJ, Redman MW, Wade JL, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) Journal Of Thoracic Oncology 2019, 14: 1839-1846. PMID: 31158500, PMCID: PMC7017958, DOI: 10.1016/j.jtho.2019.05.029.
Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.Gutierrez M, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study. Journal Of Clinical Oncology 2019, 37: tps9117-tps9117. DOI: 10.1200/jco.2019.37.15_suppl.tps9117.
Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.Hui R, Nishio M, Reck M, Rodriguez-Abreu D, Fouad T, Flaim D, Yin L, Dang T, Herbst R. Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006. Journal Of Clinical Oncology 2019, 37: tps9118-tps9118. DOI: 10.1200/jco.2019.37.15_suppl.tps9118.
A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).Bazhenova L, Redman M, Gettinger S, Hirsch F, Mack P, Schwartz L, Gandara D, Bradley J, Stinchcombe T, Leighl N, Ramalingam S, Tavernier S, Minichiello K, Kelly K, Papadimitrakopoulou V, Herbst R. A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). Journal Of Clinical Oncology 2019, 37: 9014-9014. DOI: 10.1200/jco.2019.37.15_suppl.9014.
A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).Owonikoko T, Redman M, Byers L, Hirsch F, Mack P, Schwartz L, Bradley J, Stinchcombe T, Leighl N, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam S, Herbst R, Papadimitrakopoulou V, Gandara D. A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). Journal Of Clinical Oncology 2019, 37: 9022-9022. DOI: 10.1200/jco.2019.37.15_suppl.9022.
Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).Waqar S, Redman M, Arnold S, Hirsch F, Mack P, Schwartz L, Gandara D, Stinchcombe T, Leighl N, Ramalingam S, Tanna S, Raddin R, Minichiello K, Kelly K, Bradley J, Herbst R, Papadimitrakopoulou V. Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753). Journal Of Clinical Oncology 2019, 37: 9075-9075. DOI: 10.1200/jco.2019.37.15_suppl.9075.
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancerHastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer Annals Of Oncology 2019, 30: 1311-1320. PMID: 31086949, PMCID: PMC6683857, DOI: 10.1093/annonc/mdz141.
Larotrectinib in NTRK-Rearranged Solid TumorsWilson FH, Herbst RS. Larotrectinib in NTRK-Rearranged Solid Tumors Biochemistry 2019, 58: 1555-1557. PMID: 30865435, PMCID: PMC7356829, DOI: 10.1021/acs.biochem.9b00126.
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) Journal For ImmunoTherapy Of Cancer 2019, 7: 65. PMID: 30850021, PMCID: PMC6408760, DOI: 10.1186/s40425-019-0540-1.
Immune Checkpoint Inhibitor–Associated PericarditisAltan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL. Immune Checkpoint Inhibitor–Associated Pericarditis Journal Of Thoracic Oncology 2019, 14: 1102-1108. PMID: 30851443, PMCID: PMC6617516, DOI: 10.1016/j.jtho.2019.02.026.
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapyWang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O’Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy Nature Medicine 2019, 25: 656-666. PMID: 30833750, PMCID: PMC7175920, DOI: 10.1038/s41591-019-0374-x.
The fork in the road: Waun Ki Hong, John Mendelsohn, and the reinvigoration of The University of Texas MD Anderson Cancer CenterKhuri FR, Herbst RS. The fork in the road: Waun Ki Hong, John Mendelsohn, and the reinvigoration of The University of Texas MD Anderson Cancer Center Cancer 2019, 125: 1593-1596. PMID: 30825386, DOI: 10.1002/cncr.32045.
Tumor-Infiltrating Lymphocytes—Location for Prognostic EvaluationPeled M, Onn A, Herbst RS. Tumor-Infiltrating Lymphocytes—Location for Prognostic Evaluation Clinical Cancer Research 2019, 25: 1449-1451. PMID: 30567833, DOI: 10.1158/1078-0432.ccr-18-3803.
Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In VivoCodina A, Renauer PA, Wang G, Chow RD, Park JJ, Ye H, Zhang K, Dong MB, Gassaway B, Ye L, Errami Y, Shen L, Chang A, Jain D, Herbst RS, Bosenberg M, Rinehart J, Fan R, Chen S. Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo Cell Systems 2019, 8: 136-151.e7. PMID: 30797773, PMCID: PMC6592847, DOI: 10.1016/j.cels.2019.01.004.
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung CancerLee JW, Zhang Y, Eoh KJ, Sharma R, Sanmamed MF, Wu J, Choi J, Park HS, Iwasaki A, Kaftan E, Chen L, Papadimitrakopoulou V, Herbst RS, Koo JS. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer Journal Of Thoracic Oncology 2019, 14: 1046-1060. PMID: 30771521, PMCID: PMC6542636, DOI: 10.1016/j.jtho.2019.02.004.
Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancerRiaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernethy AP, Agarwala V, Gross CP. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer Journal Of Geriatric Oncology 2019, 10: 669-672. PMID: 30718180, DOI: 10.1016/j.jgo.2019.01.016.
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trialHerbst RS, Baas P, Perez-Gracia JL, Felip E, Kim D, Han J, Molina JR, Kim J, Arvis C, Ahn M, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial Annals Of Oncology 2019, 30: 281-289. PMID: 30657853, PMCID: PMC6931268, DOI: 10.1093/annonc/mdy545.
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2019, 30: 281-289. PMID: 31987426, DOI: 10.1093/annonc/mdy545.
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLCBarlesi F, Garon E, Kim D, Felip E, Han J, Kim J, Ahn M, Fidler M, Gubens M, de Castro G, Surmont V, Li Q, Deitz A, Lubiniecki G, Herbst R. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC Journal Of Thoracic Oncology 2019, 14: 793-801. PMID: 30711649, DOI: 10.1016/j.jtho.2019.01.016.
LBA4 Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembroHerbst R, Garon E, Kim D, Cho B, Gracia J, Han J, Arvis C, Majem M, Forster M, Monnet I, Novello S, Szalai Z, Gubens M, Su W, Ceresoli G, Samkari A, Jensen E, Lubiniecki G, Baas P. LBA4 Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro Annals Of Oncology 2018, 29: x42-x43. DOI: 10.1093/annonc/mdy511.003.
Should chemotherapy plus immune checkpoint inhibition be the standard front‐line therapy for patients with metastatic non–small cell lung cancer?Goldberg SB, Herbst RS. Should chemotherapy plus immune checkpoint inhibition be the standard front‐line therapy for patients with metastatic non–small cell lung cancer? Cancer 2018, 124: 4592-4596. PMID: 30383887, PMCID: PMC6443243, DOI: 10.1002/cncr.31681.
Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or MelanomaCampbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.
Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro).Herbst RS, Garon EB, Kim DW, Chul Cho B, Pérez Gracia JL, Han JY, Dubos Arvis C, Majem M, Forster M, Monnet I, Novello S, Szalai Z, Gubens MA, Su WC, Ceresoli GL, Samkari A, Jensen E, Lubiniecki GM, Baas P. Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2018, 29 Suppl 8: viii749. PMID: 32138044, DOI: 10.1093/annonc/mdy424.075.
P2.04-20 Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLCAltan M, Toki M, Carvajal-Hausdorf D, Gettinger S, Herbst R, Rimm D. P2.04-20 Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLC Journal Of Thoracic Oncology 2018, 13: s738. DOI: 10.1016/j.jtho.2018.08.1244.
LBA63 Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)Herbst R, Garon E, Kim D, Cho B, Gracia J, Han J, Arvis C, Majem M, Forster M, Monnet I, Novello S, Szalai Z, Gubens M, Su W, Ceresoli G, Samkari A, Jensen E, Lubiniecki G, Baas P. LBA63 Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro) Annals Of Oncology 2018, 29: viii749. DOI: 10.1093/annonc/mdy424.075.
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancerRuder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG. Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer Oncotarget 2018, 9: 33995-34008. PMID: 30338041, PMCID: PMC6188056, DOI: 10.18632/oncotarget.26129.
Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancerHastings K, Gettinger S, Jungmin C, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick M, Schlessinger J, Goldberg S, Chiang A, Melero I, Agorreta J, Montuenga L, Lifton R, Ferrone S, Kavathas P, Rimm D, Kaech S, Schalper K, Herbst R, Politi K. Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer Cancer Immunology Research 2018, 6: a09-a09. DOI: 10.1158/2326-6074.tumimm17-a09.
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockersGettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers Nature Communications 2018, 9: 3196. PMID: 30097571, PMCID: PMC6086912, DOI: 10.1038/s41467-018-05032-8.
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology SettingPresley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting JAMA 2018, 320: 469-477. PMID: 30088010, PMCID: PMC6142984, DOI: 10.1001/jama.2018.9824.
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I studyHorn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study European Journal Of Cancer 2018, 101: 201-209. PMID: 30077125, DOI: 10.1016/j.ejca.2018.06.031.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) Journal For ImmunoTherapy Of Cancer 2018, 6: 75. PMID: 30012210, PMCID: PMC6048854, DOI: 10.1186/s40425-018-0382-2.
Abstract 1681: Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumorsMorgado M, Datar I, Wang J, Sanmamed M, McEachern K, Jenkins D, Chen L, Carvajal-Hausdorf D, Rimm D, Herbst R, Schalper K. Abstract 1681: Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumors Cancer Research 2018, 78: 1681-1681. DOI: 10.1158/1538-7445.am2018-1681.
Abstract 3334: CREB is required for KRAS -driven lung tumorigenesisLee J, Slack F, Nestler E, Herbst R, Koo J. Abstract 3334: CREB is required for KRAS -driven lung tumorigenesis Cancer Research 2018, 78: 3334-3334. DOI: 10.1158/1538-7445.am2018-3334.
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCRolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan D, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC Journal Of Thoracic Oncology 2018, 13: 1248-1268. PMID: 29885479, DOI: 10.1016/j.jtho.2018.05.030.
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)Arkenau H, Martin‐Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF) The Oncologist 2018, 23: 1407-e136. PMID: 29853658, PMCID: PMC6292555, DOI: 10.1634/theoncologist.2018-0044.
Defining and Understanding Adaptive Resistance in Cancer ImmunotherapyKim TK, Herbst RS, Chen L. Defining and Understanding Adaptive Resistance in Cancer Immunotherapy Trends In Immunology 2018, 39: 624-631. PMID: 29802087, PMCID: PMC6066429, DOI: 10.1016/j.it.2018.05.001.
Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Journal Of Clinical Oncology 2018, 36: 2009-2009. DOI: 10.1200/jco.2018.36.15_suppl.2009.
Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. Journal Of Clinical Oncology 2018, 36: 9099-9099. DOI: 10.1200/jco.2018.36.15_suppl.9099.
Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC).Henick B, Datar I, Villarroel-Espindola F, Sanmamed M, Yu J, Tuktamyshov R, Li A, Toki M, Syrigos K, Rimm D, Chen L, Herbst R, Schalper K. Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC). Journal Of Clinical Oncology 2018, 36: 12002-12002. DOI: 10.1200/jco.2018.36.15_suppl.12002.
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.Socinski M, Von Pawel J, Kasahara K, Bondarenko I, Syrigos K, Vladimirov V, Bryl M, Zereu M, Bair A, Hilton F, Liau K, Herbst R. A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. Journal Of Clinical Oncology 2018, 36: 109-109. DOI: 10.1200/jco.2018.36.15_suppl.109.
Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).Datar I, Villarroel-Espindola F, Henick B, Syrigos K, Toki M, Rimm D, Ferrone S, Herbst R, Schalper K. Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2018, 36: 12015-12015. DOI: 10.1200/jco.2018.36.15_suppl.12015.
Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.Herbst R, Chau I, Petrylak D, Arkenau H, Bendell J, Santana-Davila R, Calvo E, Penel N, Martin-Liberal J, Soriano A, Cassier P, Krebs M, Isambert N, Widau R, Mi G, Jin J, Ferry D, Fuchs C, Paz-Ares L. Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy. Journal Of Clinical Oncology 2018, 36: 3059-3059. DOI: 10.1200/jco.2018.36.15_suppl.3059.
First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.Papadimitrakopoulou V, Redman M, Gandara D, Hirsch F, Mack P, Langer C, Edelman M, Aggarwal C, Socinski M, Gettinger S, Waqar S, Griffin K, Leighl N, Owonikoko T, Bradley J, Ramalingam S, Stinchcombe T, Blanke C, Kelly K, Herbst R. First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP. Journal Of Clinical Oncology 2018, 36: 9019-9019. DOI: 10.1200/jco.2018.36.15_suppl.9019.
Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study.Owonikoko T, Redman M, Byers L, Griffin K, Hirsch F, Mack P, Gandara D, Bradley J, Stinchcombe T, Kelly K, Ramalingam S, Herbst R, Papadimitrakopoulou V. Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study. Journal Of Clinical Oncology 2018, 36: 9055-9055. DOI: 10.1200/jco.2018.36.15_suppl.9055.
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical ResectionWu YL, Herbst R, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection Clinical Lung Cancer 2018, 19: e533-e536. PMID: 29789220, DOI: 10.1016/j.cllc.2018.04.004.
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNAGoldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, Gettinger S, Wilson LD, Herbst RS, Patel AA. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA Clinical Cancer Research 2018, 24: 1872-1880. PMID: 29330207, PMCID: PMC5899677, DOI: 10.1158/1078-0432.ccr-17-1341.
Treatment of Advanced Non–Small Cell Lung Cancer in 2018Doroshow DB, Herbst RS. Treatment of Advanced Non–Small Cell Lung Cancer in 2018 JAMA Oncology 2018, 4: 569-570. PMID: 29494728, DOI: 10.1001/jamaoncol.2017.5190.
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung CancerVillarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos K, Toki M, Zhao H, Chen L, Herbst RS, Schalper KA. Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer Clinical Cancer Research 2018, 24: 1562-1573. PMID: 29203588, PMCID: PMC5884702, DOI: 10.1158/1078-0432.ccr-17-2542.
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-upKadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up Annals Of Oncology 2018, 29: 1072. PMID: 29688333, PMCID: PMC6887935, DOI: 10.1093/annonc/mdx062.
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung CancerGettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst R. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer Journal Of Thoracic Oncology 2018, 13: 831-839. PMID: 29578107, PMCID: PMC6485248, DOI: 10.1016/j.jtho.2018.03.008.
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysisLee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis JAMA Oncology 2018, 4: 210-216. PMID: 29270615, PMCID: PMC5838598, DOI: 10.1001/jamaoncol.2017.4427.
Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).Chau I, Penel N, Arkenau H, Santana-Davila R, Calvo E, Soriano A, Mi G, Jin J, Ferry D, Herbst R, Fuchs C. Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF). Journal Of Clinical Oncology 2018, 36: 101-101. DOI: 10.1200/jco.2018.36.4_suppl.101.
The biology and management of non-small cell lung cancerHerbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer Nature 2018, 553: 446-454. PMID: 29364287, DOI: 10.1038/nature25183.
60 How to Promote and Organize Clinical Research in Lung CancerBarlesi F, Mazieres J, Zhou Y, Herbst R, Zalcman G. 60 How to Promote and Organize Clinical Research in Lung Cancer 2018, 628-634.e2. DOI: 10.1016/b978-0-323-52357-8.00060-3.
Contributors † Deceased.Adjei A, Ahn M, Amos C, Antonicelli A, Asamura H, Atwood T, Baas P, Bailey-Wilson J, Ball D, Barlesi F, Bazan J, Belderbos J, Bezjak A, Billingham L, Boffetta P, Bonifazi M, Brahmer J, Brambilla E, Brims F, Brunelli A, Bryant A, Campbell N, Carter B, Cerfolio R, Cho B, Cho W, Choy H, Chu C, Colburn G, Colt H, Costa R, Darling G, Davis M, de Groot P, de Koning H, De Leyn P, De Ruysscher D, Demiral A, Derks J, Detterbeck F, Devarakonda S, Dingemans A, Donington J, Dresler C, Dubinett S, Dy G, Erasmus J, Fairchild A, Fennell D, Fernando H, Filosso P, Flores R, Fong K, Fox J, Gandara D, Gandhi L, Gaspar L, Gasparini S, Gazdar A, Giaccone G, Girard N, Goldstraw P, Gore E, Goss G, Govindan R, Greenberg A, Grunenwald D, Guckenberger M, Gulati S, Hassan R, Hazzard C, Hegi F, Hensing T, Herbst R, Hirsch F, Horeweg N, Jablons D, Jett J, Kaufman A, Keall P, Kelly K, Kong F, Kubota K, Laird-Offringa I, Lara P, Laskin J, Le Q, Le Péchoux C, Liclican E, Lievens Y, Lin C, Loo B, Manus M, Macapinlac H, Macbeth F, Mackillop W, Maher C, Mambetsariev I, Mandrekar S, Mansfield A, Marks L, Mascaux C, Massion P, Mazieres J, McWilliams A, Mitsudomi T, Mok T, Morgensztern D, Mornex F, Mulshine J, Munden R, Nackaerts K, Nakamichi S, Noguchi M, Noonan K, Novello S, Nowak A, O’Byrne K, Ohri N, Okada M, Ostroff J, Parikh M, Park E, Park K, Pass H, Pastis N, Paz-Ares L, Pennell N, Perol M, Pillai R, Postmus P, Ramalingham S, Ramella S, Rami-Porta R, Reck M, Redman M, Reinmuth N, Ricardi U, Rice D, Ridge C, Rom W, Rosenzweig K, Ruffini E, Rusch V, Salgia R, Sanchez-Cespedes M, Saqi A, Scagliotti G, Schimmel S, Schwartz A, Senan S, Shepherd F, Siegfried J, Silvestri G, Simon G, Smit E, Solomon S, Stabile L, Steliga M, Stinchcombe T, Stollenwerk N, Sun J, Thomas A, Tsao M, Tsay J, Van Houtte P, Van Schil P, van Zandwijk N, Vansteenkiste J, Varella-Garcia M, Veronesi G, Vinod S, Vokes E, Wakelee H, Walser T, Watanabe S, Weder W, Wei B, Wistuba I, Yang J, Yankelevitz D, Yasufuku K, Yoneda K, Zalcman G, Zhou C, Zhou Y, Zips D. Contributors † Deceased. 2018, v-xi. DOI: 10.1016/b978-0-323-52357-8.01002-7.
Chapter 6 Management of Advanced Non–Small Cell Lung Cancer Noncurative Intent TreatmentXia B, Herbst R. Chapter 6 Management of Advanced Non–Small Cell Lung Cancer Noncurative Intent Treatment 2018, 99-115. DOI: 10.1016/b978-0-323-48565-4.00006-0.
Immune Checkpoint Inhibition in Lung CancerMorgensztern D, Herbst R. Immune Checkpoint Inhibition in Lung Cancer 2017, 333-344. DOI: 10.1007/978-3-319-62431-0_20.
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung CancerGettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer Cancer Discovery 2017, 7: cd-17-0593. PMID: 29025772, PMCID: PMC5718941, DOI: 10.1158/2159-8290.cd-17-0593.
15PD In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockersDatar I, Sanmamed M, Choi J, Wang J, Henick B, Badri T, Mejias L, Lozano M, Gracia J, Velcheti V, Herbst R, Melero I, Chen L, Schalper K. 15PD In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers Annals Of Oncology 2017, 28: xi5. DOI: 10.1093/annonc/mdx710.006.
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 studyHerbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study The Lancet Oncology 2017, 19: 101-114. PMID: 29169877, PMCID: PMC5847342, DOI: 10.1016/s1470-2045(17)30694-0.
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockersNilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers Science Translational Medicine 2017, 9 PMID: 29118262, PMCID: PMC5870120, DOI: 10.1126/scitranslmed.aao4307.
PS04.01 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection Topic: Medical OncologyHerbst R, Wu Y, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. PS04.01 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection Topic: Medical Oncology Journal Of Thoracic Oncology 2017, 12: s1576. DOI: 10.1016/j.jtho.2017.09.070.
MA 07.14 Change in Practice Patterns from an Online NSCLC Treatment Decision Support ToolGandara D, Herbst R, Mok T, Ramalingam S, Obholz K, Quill T, Chow H, Scagliotti G. MA 07.14 Change in Practice Patterns from an Online NSCLC Treatment Decision Support Tool Journal Of Thoracic Oncology 2017, 12: s1830-s1831. DOI: 10.1016/j.jtho.2017.09.514.
P2.04-006 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor ResectionHerbst R, Wu Y, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. P2.04-006 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection Journal Of Thoracic Oncology 2017, 12: s2399-s2400. DOI: 10.1016/j.jtho.2017.11.019.
Immuno-thermal ablations – boosting the anticancer immune responseSlovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS. Immuno-thermal ablations – boosting the anticancer immune response Journal For ImmunoTherapy Of Cancer 2017, 5: 78. PMID: 29037259, PMCID: PMC5644150, DOI: 10.1186/s40425-017-0284-8.
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung CancerShien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer Molecular Cancer Therapeutics 2017, 16: 2234-2245. PMID: 28729401, PMCID: PMC5628136, DOI: 10.1158/1535-7163.mct-17-0148.
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung CancerCascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer Clinical Cancer Research 2017, 23: 5489-5501. PMID: 28559461, PMCID: PMC5600821, DOI: 10.1158/1078-0432.ccr-16-3216.
1341P Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNAGoldberg S, Narayan A, Kole A, Decker R, Teysir J, Carriero N, Lee A, Nemati R, Nath S, Mane S, Deng Y, Sukumar N, Zelterman D, Boffa D, Politi K, Gettinger S, Wilson L, Herbst R, Patel A. 1341P Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA Annals Of Oncology 2017, 28: v478. DOI: 10.1093/annonc/mdx380.043.
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating LymphocytesAltan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes Clinical Cancer Research 2017, 23: 5202-5209. PMID: 28539467, PMCID: PMC5581684, DOI: 10.1158/1078-0432.ccr-16-3107.
Lung Endothelial MicroRNA-1 Regulates Tumor Growth and AngiogenesisKorde A, Jin L, Zhang JG, Ramaswamy A, Hu B, Kolahian S, Guardela BJ, Herazo-Maya J, Siegfried JM, Stabile L, Pisani MA, Herbst RS, Kaminski N, Elias JA, Puchalski JT, Takyar SS. Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis American Journal Of Respiratory And Critical Care Medicine 2017, 196: 1443-1455. PMID: 28853613, PMCID: PMC5736970, DOI: 10.1164/rccm.201610-2157oc.
Co-Option of the Extracellular Matrix During Lung Cancer Metastasis and Therapeutic RepsonseStevens L, Adua S, Arnal-Estapé A, Zhao M, Barlaskar F, Herbst R, Nguyen D. Co-Option of the Extracellular Matrix During Lung Cancer Metastasis and Therapeutic Repsonse Journal Of Thoracic Oncology 2017, 12: s1543. DOI: 10.1016/j.jtho.2017.06.049.
Abstract 1635: Multiplexed analysis of fixed tumor tissues using imaging mass cytometryVillarroel-Espindola F, Carvajal-Hausdorf D, Datar I, Esch A, Rashidi N, Nassar A, Ren S, Montgomery R, Herbst R, Rimm D, Schalper K. Abstract 1635: Multiplexed analysis of fixed tumor tissues using imaging mass cytometry Cancer Research 2017, 77: 1635-1635. DOI: 10.1158/1538-7445.am2017-1635.
Abstract 5600: Simultaneous measurement and clinical significance of PD-1, LAG-3 and TIM-3 in non-small cell lung cancer (NSCLC)Datar I, Wang J, Mani N, Villarroel-Espindola F, Ryan P, Sanmamed M, McEachern K, Jenkins D, Rimm D, Chen L, Herbst R, Schalper K. Abstract 5600: Simultaneous measurement and clinical significance of PD-1, LAG-3 and TIM-3 in non-small cell lung cancer (NSCLC) Cancer Research 2017, 77: 5600-5600. DOI: 10.1158/1538-7445.am2017-5600.
Abstract 5657: Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC)Villarroel-Espindola F, Datar I, Velcheti V, Rimm D, Herbst R, Schalper K. Abstract 5657: Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC) Cancer Research 2017, 77: 5657-5657. DOI: 10.1158/1538-7445.am2017-5657.
Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study.Arkenau HT, Bendell J, Herbst R, Mi G, Jin J, Rege J, Ferry D, Chau I. Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2017, 28 Suppl 3: iii144-iii145. PMID: 32135778, DOI: 10.1093/annonc/mdx262.018.
O-019 Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 studyArkenau H, Bendell J, Herbst R, Mi G, Jin J, Rege J, Ferry D, Chau I. O-019 Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study Annals Of Oncology 2017, 28: iii144-iii145. DOI: 10.1093/annonc/mdx262.018.
Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.Presley C, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy A, Agarwala V, Gross C. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2017, 35: 6563-6563. DOI: 10.1200/jco.2017.35.15_suppl.6563.
Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.Datar I, Mani N, Henick B, Wurtz A, Kaftan E, Herbst R, Rimm D, Gettinger S, Politi K, Schalper K. Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers. Journal Of Clinical Oncology 2017, 35: e14611-e14611. DOI: 10.1200/jco.2017.35.15_suppl.e14611.
Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC).Henick B, Goldberg S, Narayan A, Rossi C, Rodney S, Kole A, Politi K, Gettinger S, Herbst R, Patel A. Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2017, 35: e20652-e20652. DOI: 10.1200/jco.2017.35.15_suppl.e20652.
Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.Chau I, Bendell J, Calvo E, Santana-Davila R, Arkenau H, Mi G, Jin J, Rege J, Ferry D, Herbst R, Fuchs C. Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. Journal Of Clinical Oncology 2017, 35: 4046-4046. DOI: 10.1200/jco.2017.35.15_suppl.4046.
Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data.Jalali A, Wang J, Lee W, Zhang J, Wu C, Gibbons D, Tang X, Kalhor N, Izzo J, Behrens C, Fossella F, Tsao A, Lee J, Swisher S, Heymach J, Futreal A, Wistuba I, Herbst R, Papadimitrakopoulou V, Zhang J. Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data. Journal Of Clinical Oncology 2017, 35: 8538-8538. DOI: 10.1200/jco.2017.35.15_suppl.8538.
A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.Wade J, Langer C, Redman M, Aggarwal C, Bradley J, Crawford J, Miao J, Griffin K, Herbst R, Kelly K, Gandara D, Papadimitrakopoulou V. A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B. Journal Of Clinical Oncology 2017, 35: 9054-9054. DOI: 10.1200/jco.2017.35.15_suppl.9054.
Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.Aggarwal C, Redman M, Lara P, Borghaei H, Hoffman P, Bradley J, Griffin K, Miao J, Mack P, Papadimitrakopoulou V, Herbst R, Kelly K, Gandara D. Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D. Journal Of Clinical Oncology 2017, 35: 9055-9055. DOI: 10.1200/jco.2017.35.15_suppl.9055.
A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.Edelman M, Redman M, Albain K, McGary E, Rafique N, Petro D, Waqar S, Miao J, Griffin K, Papadimitrakopoulou V, Kelly K, Gandara D, Herbst R. A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C. Journal Of Clinical Oncology 2017, 35: 9056-9056. DOI: 10.1200/jco.2017.35.15_suppl.9056.
Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J, Molina J, Kim J, Dubos Arvis C, Ahn M, Majem M, Fidler M, Castro G, Garrido M, Ellison M, Samkari A, Lubiniecki G, Garon E. Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010. Journal Of Clinical Oncology 2017, 35: 9090-9090. DOI: 10.1200/jco.2017.35.15_suppl.9090.
Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer SurgerySalazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, Herbst RS, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery JAMA Oncology 2017, 3: 610-619. PMID: 28056112, PMCID: PMC5824207, DOI: 10.1001/jamaoncol.2016.5829.
Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop ReportNewman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop Report American Journal Of Respiratory And Critical Care Medicine 2017, 195: 1661-1670. PMID: 28430547, PMCID: PMC5476915, DOI: 10.1164/rccm.201701-0150ws.
The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual MeetingKaufman H, Atkins M, Dicker A, Jim H, Garrison L, Herbst R, McGivney W, Silverstein S, Wigginton J, Yu P. The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting Journal For ImmunoTherapy Of Cancer 2017, 5: 38. PMCID: PMC5394621, DOI: 10.1186/s40425-017-0241-6.
Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of MicrometastasesStevens LE, Cheung WKC, Adua SJ, Arnal-Estapé A, Zhao M, Liu Z, Brewer K, Herbst RS, Nguyen DX. Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases Cancer Research 2017, 77: 1905-1917. PMID: 28196904, PMCID: PMC5468792, DOI: 10.1158/0008-5472.can-16-1978.
143TiP IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLCJassem J, de Marinis F, Spigel D, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Herbst R. 143TiP IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC Annals Of Oncology 2017, 28: ii50. DOI: 10.1093/annonc/mdx091.063.
90PD Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety dataHerbst R, Martin-Liberal J, Calvo E, Isambert N, Bendell J, Cassier P, Jin J, Mi G, Rege J, Paz-Ares L. 90PD Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data Annals Of Oncology 2017, 28: ii32-ii33. DOI: 10.1093/annonc/mdx091.010.
83O A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400APapadimitrakopoulou V, Redman M, Borghaei H, Waqar S, Robert F, Kiefer G, McDonough S, Herbst R, Kelly K, Gandara D. 83O A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A Annals Of Oncology 2017, 28: ii29. DOI: 10.1093/annonc/mdx091.003.
Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010.Hellmann M, Ma J, Garon E, Hui R, Gandhi L, Soria J, Anderson K, Lubiniecki G, Piperdi B, Herbst R. Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010. Journal Of Clinical Oncology 2017, 35: 77-77. DOI: 10.1200/jco.2017.35.7_suppl.77.
Cancer of the LungLu C, Morgensztern D, Chiang A, Onn A, Sepesi B, Vaporciyan A, Chang J, Komaki R, Wistuba I, Herbst R. Cancer of the Lung 2017, 1-30. DOI: 10.1002/9781119000822.hfcm085.
A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.Petrylak D, Arkenau H, Perez-Gracia J, Krebs M, Santana-Davila R, Yang J, Rege J, Mi G, Ferry D, Herbst R. A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma. Journal Of Clinical Oncology 2017, 35: 349-349. DOI: 10.1200/jco.2017.35.6_suppl.349.
Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies.Zhong H, Fazenbaker C, Chen C, Breen S, Huang J, Yao X, Ren P, Yao Y, Herbst R, Hollingsworth RE. Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies. Oncogene 2017, 36: 797-806. PMID: 27399333, DOI: 10.1038/onc.2016.248.
Evolving Treatment Options for Lung CancerMorgensztern D, Herbst RS. Evolving Treatment Options for Lung Cancer Hematology/Oncology Clinics Of North America 2017, 31: xiii-xiv. PMID: 27912837, DOI: 10.1016/j.hoc.2016.09.001.
Immunotherapy in Lung CancerDu L, Herbst RS, Morgensztern D. Immunotherapy in Lung Cancer Hematology/Oncology Clinics Of North America 2017, 31: 131-141. PMID: 27912829, DOI: 10.1016/j.hoc.2016.08.004.
Lung CancerMorgensztern D, Herbst R. Lung Cancer Hematology/Oncology Clinics Of North America 2017, 31: i. DOI: 10.1016/s0889-8588(16)30151-4.
Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).Chau I, Bendell J, Calvo E, Santana-Davila R, Rodon Ahnert J, Penel N, Arkenau H, Yang J, Rege J, Mi G, Ferry D, Herbst R, Fuchs C. Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). Journal Of Clinical Oncology 2017, 35: 102-102. DOI: 10.1200/jco.2017.35.4_suppl.102.
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung CancerSchalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer Clinical Cancer Research 2017, 23: 370-378. PMID: 27440266, PMCID: PMC6350535, DOI: 10.1158/1078-0432.ccr-16-0150.
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-upKadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up Annals Of Oncology 2017, 28: 75-82. PMID: 27687306, PMCID: PMC5982809, DOI: 10.1093/annonc/mdw436.
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune functionChoi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function Annals Of Oncology 2017, 28: 83-89. PMID: 28177435, PMCID: PMC6246501, DOI: 10.1093/annonc/mdw437.
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2017, 28: 75-82. PMID: 31792518, DOI: 10.1093/annonc/mdw436.
MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)Gettinger S, Choi J, Mani N, Datar I, Kaftan E, Goldberg S, Zelterman D, Politi K, Lifton R, Rimm D, Herbst R, Schalper K. MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC) Journal Of Thoracic Oncology 2017, 12: s430-s431. DOI: 10.1016/j.jtho.2016.11.501.
MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung AdenocarcinomasHastings K, Choi J, Wurtz A, Walther Z, Cai G, Oliva I, Zhao Z, Gaffney S, Iamarino A, Zhao S, Bi M, Goldberg S, Chiang A, Liu Z, Townsend J, Schlessinger J, Lifton R, Herbst R, Gettinger S, Politi K. MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas Journal Of Thoracic Oncology 2017, 12: s435. DOI: 10.1016/j.jtho.2016.11.507.
P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT BiomarkersChoi J, Sowell R, Truini A, Schalper K, Wurtz A, Cai G, Perry C, Datar I, Hastings K, Melnick M, Kaftan E, Kavathas P, Kaech S, Rimm D, Goldberg S, Chiang A, Lifton R, Chen L, Herbst R, Politi K, Gettinger S. P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT Biomarkers Journal Of Thoracic Oncology 2017, 12: s1331-s1332. DOI: 10.1016/j.jtho.2016.11.1884.
P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: ITDecker R, Goldberg S, Nath S, Husain Z, Lilenbaum R, Schalper K, Chiang A, Altan M, Zelterman D, Kaech S, Herbst R, Gettinger S. P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: IT Journal Of Thoracic Oncology 2017, 12: s1303-s1304. DOI: 10.1016/j.jtho.2016.11.1843.
P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and BiomarkersRothberg B, Das R, Jackson L, Lazowski H, Bai Y, O'Neill D, Roberts S, Rothberg J, Herbst R, Kim A, Boffa D, Rimm D, Detterbeck F, Tanoue L. P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and Biomarkers Journal Of Thoracic Oncology 2017, 12: s623-s624. DOI: 10.1016/j.jtho.2016.11.801.
P2.03b-053 Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab Topic: BiomarkersMack P, Moon J, Herbst R, Kim E, Semrad T, Redman M, Tsai R, Solis L, Gregg J, Hatcher S, Varella-Garcia M, Hirsch F, Blanke C, Kelly K, Gandara D. P2.03b-053 Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab Topic: Biomarkers Journal Of Thoracic Oncology 2017, 12: s967-s968. DOI: 10.1016/j.jtho.2016.11.1334.
P2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC Topic: Immune Mechanisms in Thoracic Cancer and Targeted TherapyAltan M, Pelekanou V, Schalper K, Toki M, Herbst R, Rimm D. P2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy Journal Of Thoracic Oncology 2017, 12: s813-s814. DOI: 10.1016/j.jtho.2016.11.1098.
OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed PembrolizumabHerbst R, Garon E, Kim D, Cho B, Gadgeel S, Léna H, Gúrpide A, Han J, Arvis C, Majem M, Forster M, Monnet I, Novello S, Saka H, Szalai Z, Gubens M, Su W, Lubiniecki G, Shentu Y, Ferraro G, Baas P. OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab Journal Of Thoracic Oncology 2017, 12: s254-s255. DOI: 10.1016/j.jtho.2016.11.243.
P3.02c-070 Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model Topic: IT BiomarkersLee J, Zhang Y, Choi J, Sharma R, Park H, Kaftan E, Papadimitrakopoulou V, Herbst R, Koo J. P3.02c-070 Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model Topic: IT Biomarkers Journal Of Thoracic Oncology 2017, 12: s1319. DOI: 10.1016/j.jtho.2016.11.1865.
P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients Topic: ITDe Marinis F, Jassem J, Spigel D, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giacconne G, Herbst R. P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients Topic: IT Journal Of Thoracic Oncology 2017, 12: s1299-s1300. DOI: 10.1016/j.jtho.2016.11.1837.
MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening UpdatesPapadimitrakopoulou V, Redman M, Gandara D, Hirsch F, Mack P, Borghaei H, Langer C, Wade J, Edelman M, Albain K, Lara P, Aggarwal C, Socinski M, Gettinger S, Bazhenova L, Malik S, Miller V, Mcdonough S, Sigal E, Kelly K, Herbst R. MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates Journal Of Thoracic Oncology 2017, 12: s439-s440. DOI: 10.1016/j.jtho.2016.11.513.
480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts)De Marinis F, Jassem J, Spigel D, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Herbst R. 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts) Annals Of Oncology 2016, 27 DOI: 10.1093/annonc/mdw594.044.
480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts)De Marinis F, Jassem J, Spigel D, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Herbst R. 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts) Annals Of Oncology 2016, 27: ix154. DOI: 10.1016/s0923-7534(21)00638-4.
Diminished but not dead: chemotherapy for the treatment of NSCLCHerbst RS, Sznol M. Diminished but not dead: chemotherapy for the treatment of NSCLC The Lancet Oncology 2016, 17: 1464-1465. PMID: 27819227, DOI: 10.1016/s1470-2045(16)30524-1.
PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy-Naive NSCLC Patients: Topic: Medical Oncology.Herbst RS, De Marinis F, Jassem J, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Spigel DR. PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy-Naive NSCLC Patients: Topic: Medical Oncology. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: S304-S305. PMID: 27969523, DOI: 10.1016/j.jtho.2016.09.091.
PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology.Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger SN. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: S309-S310. PMID: 27969529, DOI: 10.1016/j.jtho.2016.09.097.
Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, Cinciripini P, Collins B, David S, Davis J, Hitsman B, Hyland A, Lang M, Leischow S, Park ER, Purcell WT, Selzle J, Silber A, Spencer S, Tanvetyanon T, Tiep B, Tindle HA, Tucker-Seeley R, Urbanic J, Hooper MW, Weksler B, Whitlock CW, Wood DE, Burns J, Scavone J. Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2016, 14: 1430-1468. PMID: 27799513, DOI: 10.6004/jnccn.2016.0152.
PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study Topic: Medical OncologyGordon M, Herbst R, Horn L, Soria J, Gandhi L, Felip E, Sequist L, Spigel D, Antonia S, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger S. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study Topic: Medical Oncology Journal Of Thoracic Oncology 2016, 11: s309-s310. DOI: 10.1016/j.jtho.2016.09.097.
PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients Topic: Medical OncologyHerbst R, De Marinis F, Jassem J, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Spigel D. PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients Topic: Medical Oncology Journal Of Thoracic Oncology 2016, 11: s304-s305. DOI: 10.1016/j.jtho.2016.09.091.
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung CancerPapadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Journal Of Clinical Oncology 2016, 34: 3638-3647. PMID: 27480147, PMCID: PMC5065110, DOI: 10.1200/jco.2015.66.0084.
PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment.Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon EB. PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: S174-S175. PMID: 27676480, DOI: 10.1016/j.jtho.2016.08.014.
P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy.Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon EB. P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: S242-S243. PMID: 27676575, DOI: 10.1016/j.jtho.2016.08.112.
PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 AssessmentHerbst R, Baas P, Perez-Gracia J, Felip E, Kim D, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon E. PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment Journal Of Thoracic Oncology 2016, 11: s174-s175. DOI: 10.1016/j.jtho.2016.08.014.
P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment Track: ImmunotherapyHerbst R, Baas P, Perez-Gracia J, Felip E, Kim D, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon E. P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment Track: Immunotherapy Journal Of Thoracic Oncology 2016, 11: s242-s243. DOI: 10.1016/j.jtho.2016.08.112.
1219P Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLCBarlesi F, Garon E, Kim D, Felip E, Han J, Kim J, Ahn M, Fidler M, Gubens M, Castro G, Surmont V, Li Q, Deitz A, Lubiniecki G, Herbst R. 1219P Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC Annals Of Oncology 2016, 27: vi422. DOI: 10.1093/annonc/mdw383.19.
LBA38 Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)Herbst R, Martin-Liberal J, Calvo E, Isambert N, Bendell J, Cassier P, Perez-Gracia J, Yang J, Rege J, Mi G, Ferry D, Paz-Ares L. LBA38 Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P) Annals Of Oncology 2016, 27: vi574. DOI: 10.1093/annonc/mdw435.34.
LBA48 Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010Herbst R, Baas P, Kim D, Felip E, Pérez-Gracia J, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, De Castro G, Garrido M, Shentu Y, Lubiniecki G, Garon E. LBA48 Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010 Annals Of Oncology 2016, 27: vi583. DOI: 10.1093/annonc/mdw435.47.
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.Choi M, Kadara H, Zhang J, Cuentas EP, Canales JR, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee JJ, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2016 PMID: 27687303, DOI: 10.1093/annonc/mdw437.
Nivolumab and Pembrolizumab for Non–Small Cell Lung CancerMorgensztern D, Herbst RS. Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer Clinical Cancer Research 2016, 22: 3713-3717. PMID: 27252413, DOI: 10.1158/1078-0432.ccr-15-2998.
Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinomaChoi M, Kadara H, Zhang J, Parra Cuentas E, Rodriguez Canales J, Gaffney S, Zhao Z, Behrens C, Fujimoto J, Chow C, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons D, Heymach J, Kaftan E, Townsend J, Lynch T, Schlessinger J, Lee J, Lifton R, Herbst R, Wistuba I. Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinoma Cancer Research 2016, 76: 142-142. DOI: 10.1158/1538-7445.am2016-142.
Abstract 89: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinomaKadara H, Choi M, Zhang J, Parra Cuentas E, Rodriguez Canales J, Gaffney S, Zhao Z, Behrens C, Fujimoto J, Chow C, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons D, Heymach J, Kaftan E, Townsend J, Lynch T, Schlessinger J, Lee J, Lifton R, Wistuba I, Herbst R. Abstract 89: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma Cancer Research 2016, 76: 89-89. DOI: 10.1158/1538-7445.am2016-89.
Abstract 1144: Detection of a novel ALK fusion variant in lung adenocarcinoma using a comprehensive genomic analysisShien K, Ruder D, Ileana E, Papadimitrakopoulou V, Frampton G, Behrens C, Kalhor N, Lee J, Tang X, Herbst R, Wistuba I, Izzo J. Abstract 1144: Detection of a novel ALK fusion variant in lung adenocarcinoma using a comprehensive genomic analysis Cancer Research 2016, 76: 1144-1144. DOI: 10.1158/1538-7445.am2016-1144.
Abstract 2334: Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancerLee J, Zhang Y, Park H, Park S, Koo J, Herbst R. Abstract 2334: Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancer Cancer Research 2016, 76: 2334-2334. DOI: 10.1158/1538-7445.am2016-2334.
Clinician Perspectives on Current Issues in Lung Cancer Drug DevelopmentWaqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Clinician Perspectives on Current Issues in Lung Cancer Drug Development Journal Of Thoracic Oncology 2016, 11: 1387-1396. PMID: 27401214, PMCID: PMC5131641, DOI: 10.1016/j.jtho.2016.05.009.
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trialGoldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial The Lancet Oncology 2016, 17: 976-983. PMID: 27267608, PMCID: PMC5526047, DOI: 10.1016/s1470-2045(16)30053-5.
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016 Journal Of Thoracic Oncology 2016, 11: 946-963. PMID: 27229180, DOI: 10.1016/j.jtho.2016.05.008.
Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.
Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC).Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Chiang A, Velcheti V, Kaftan E, Zhang J, Lu L, Rimm D, Han B, Lu H, Zhao H, Herbst R. Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC). Journal Of Clinical Oncology 2016, 34: 8566-8566. DOI: 10.1200/jco.2016.34.15_suppl.8566.
HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies.Xia B, Wurtz A, Gettinger S, Herbst R, Chiang A, Wan M, Sklar J, Neumeister V, Politi K, Goldberg S. HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies. Journal Of Clinical Oncology 2016, 34: 9049-9049. DOI: 10.1200/jco.2016.34.15_suppl.9049.
Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC).Schalper K, Mani N, Toki M, Carvajal-Hausdorf D, Herbst R, Rimm D. Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2016, 34: 11610-11610. DOI: 10.1200/jco.2016.34.15_suppl.11610.
Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.Herbst R, Baas P, Perez-Gracia J, Felip E, Kim D, Han J, Molina J, Kim J, Dubos Arvis C, Ahn M, Majem M, Fidler M, Surmont V, Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon E. Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC. Journal Of Clinical Oncology 2016, 34: 3030-3030. DOI: 10.1200/jco.2016.34.15_suppl.3030.
A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.Herbst R, Bendell J, Isambert N, Calvo E, Santana-Davila R, Cassier P, Perez-Gracia J, Yang J, Rege J, Ferry D, Mi G, Chau I. A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. Journal Of Clinical Oncology 2016, 34: 3056-3056. DOI: 10.1200/jco.2016.34.15_suppl.3056.
Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.Baas P, Garon E, Herbst R, Felip E, Perez-Gracia J, Han J, Molina J, Kim J, Dubos Arvis C, Ahn M, Majem M, Fidler M, Barlesi F, Castro G, Garrido M, Shentu Y, Lubiniecki G, Im E, Kim D. Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC. Journal Of Clinical Oncology 2016, 34: 9015-9015. DOI: 10.1200/jco.2016.34.15_suppl.9015.
Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.Garon E, Herbst R, Kim D, Felip E, Perez-Gracia J, Han J, Molina J, Kim J, Dubos Arvis C, Ahn M, Majem M, Fidler M, Gubens M, Castro G, Garrido M, Shentu Y, Im E, Lubiniecki G, Baas P. Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010. Journal Of Clinical Oncology 2016, 34: 9024-9024. DOI: 10.1200/jco.2016.34.15_suppl.9024.
Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer.Gaule P, Rehman J, Smithy J, Toki M, Han G, Neumeister V, Carvajal-Hausdorf D, Schalper K, Pelekanou V, Wasserman B, Herbst R, Rimm D. Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer. Journal Of Clinical Oncology 2016, 34: 9040-9040. DOI: 10.1200/jco.2016.34.15_suppl.9040.
Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).Semrad T, Redman M, Herbst R, Kim E, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold S, Varella-Garcia M, Moon J, Mack P, Blanke C, Hirsch F, Kelly K, Gandara D. Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2016, 34: 9082-9082. DOI: 10.1200/jco.2016.34.15_suppl.9082.
Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers.Papadimitrakopoulou V, Redman M, Gandara D, Hirsch F, Mack P, Borghaei H, Langer C, Engelman J, Edelman M, Albain K, Lara P, Aggarwal C, Socinski M, Gettinger S, Bazhenova L, Malik S, Miller V, Sigal E, Kelly K, Herbst R. Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers. Journal Of Clinical Oncology 2016, 34: 9088-9088. DOI: 10.1200/jco.2016.34.15_suppl.9088.
Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC.Hirsch F, Redman M, Herbst R, Kim E, Semrad T, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold S, Varella-Garcia M, Moon J, Mack P, Blanke C, Kelly K, Gandara D. Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC. Journal Of Clinical Oncology 2016, 34: 9090-9090. DOI: 10.1200/jco.2016.34.15_suppl.9090.
Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort.Presley C, Harrington E, Gippetti J, Agarwala V, Bowser B, Adelson K, Herbst R, Abernethy A, Gross C. Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort. Journal Of Clinical Oncology 2016, 34: e20621-e20621. DOI: 10.1200/jco.2016.34.15_suppl.e20621.
Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for ResearchSchalper KA, Kaftan E, Herbst RS. Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research Clinical Cancer Research 2016, 22: 2102-2104. PMID: 26957559, PMCID: PMC4940186, DOI: 10.1158/1078-0432.ccr-16-0169.
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI VandetanibNilsson MB, Giri U, Gudikote J, Tang X, Lu W, Tran H, Fan Y, Koo A, Diao L, Tong P, Wang J, Herbst R, Johnson BE, Ryan A, Webster A, Rowe P, Wistuba II, Heymach JV. KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib Clinical Cancer Research 2016, 22: 1940-1950. PMID: 26578684, PMCID: PMC4834253, DOI: 10.1158/1078-0432.ccr-15-1994.
Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer ResearchLand SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, Duffy SA, Gritz ER, Rigotti NA, Brandon TH, Prindiville SA, Sarna LP, Schnoll RA, Herbst RS, Cinciripini PM, Leischow SJ, Dresler CM, Fiore MC, Warren GW. Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research Clinical Cancer Research 2016, 22: 1907-1913. PMID: 26888828, PMCID: PMC4861174, DOI: 10.1158/1078-0432.ccr-16-0104.
GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung CancerPark SA, Lee JW, Herbst RS, Koo JS. GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer PLOS ONE 2016, 11: e0153075. PMID: 27049759, PMCID: PMC4822949, DOI: 10.1371/journal.pone.0153075.
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinomaHedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma Journal Of Clinical Investigation 2016, 126: 1606-1606. PMID: 27035818, PMCID: PMC4811141, DOI: 10.1172/jci86862.
Scientific Advances in Lung Cancer 2015Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ou S, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015 Journal Of Thoracic Oncology 2016, 11: 613-638. PMID: 27013409, DOI: 10.1016/j.jtho.2016.03.012.
Immune checkpoint therapy for non-small-cell lung cancer: an updateXia B, Herbst RS. Immune checkpoint therapy for non-small-cell lung cancer: an update Immunotherapy 2016, 8: 279-298. PMID: 26860624, DOI: 10.2217/imt.15.123.
E2F8 and its target genes as novel therapeutic targets for lung cancerPark S, Lee J, Platt J, Sweasy J, Glazer P, Herbst R, Koo J. E2F8 and its target genes as novel therapeutic targets for lung cancer Journal Of Thoracic Oncology 2016, 11: s29. DOI: 10.1016/j.jtho.2015.12.048.
Targeting PD1 and PDL1 in lung cancer treatment: Where are we now?Herbst R. Targeting PD1 and PDL1 in lung cancer treatment: Where are we now? Journal Of Thoracic Oncology 2016, 11: s8. DOI: 10.1016/j.jtho.2015.12.012.
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung CancerMcLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelakanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer JAMA Oncology 2016, 2: 1-9. PMID: 26562159, PMCID: PMC4941982, DOI: 10.1001/jamaoncol.2015.3638.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialHerbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial The Lancet 2015, 387: 1540-1550. PMID: 26712084, DOI: 10.1016/s0140-6736(15)01281-7.
LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapyHerbst R, Kim D, Felip E, Perez-Gracia J, Garon E, Han J, Molina J, Kim J, Gervais R, Ahn M, Majem M, Fidler M, De Castro G, Garrido M, Lubiniecki G, Shentu Y, Im E, Baas P. LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy Annals Of Oncology 2015, 26: ix161. DOI: 10.1093/annonc/mdv586.03.
355TiP Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLCHerbst R, de Marinis F, Jassem J, Spigel D, Shankar G, Mocci S, Sandler A, Lopez-Chavez A, Li S, Giaccone G. 355TiP Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC Annals Of Oncology 2015, 26: ix103. DOI: 10.1093/annonc/mdv528.12.
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinomaHedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma Journal Of Clinical Investigation 2015, 126: 169-180. PMID: 26619122, PMCID: PMC4701554, DOI: 10.1172/jci82066.
Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancerSchalper K, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Chen L, Sanmamed M, Herbst R, Rimm D. Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer Journal For ImmunoTherapy Of Cancer 2015, 3: p415. PMCID: PMC4652522, DOI: 10.1186/2051-1426-3-s2-p415.
AJ-2 Lung-MAP (SWOG S1400): A Biomarker-Driven Protocol Accelerating Development of Squamous Cell Lung Cancer TherapiesHerbst R. AJ-2 Lung-MAP (SWOG S1400): A Biomarker-Driven Protocol Accelerating Development of Squamous Cell Lung Cancer Therapies Annals Of Oncology 2015, 26: vii5. DOI: 10.1093/annonc/mdv400.02.
ISY8-3 Personalized immunotherapy for advanced non-small cell lung cancerHerbst R. ISY8-3 Personalized immunotherapy for advanced non-small cell lung cancer Annals Of Oncology 2015, 26: vii16. DOI: 10.1093/annonc/mdv410.02.
Targeted Therapy in Solid Tumors: Lung CancerWaqar S, Morgensztern D, Herbst R. Targeted Therapy in Solid Tumors: Lung Cancer 2015, 224-230. DOI: 10.1002/9781118468678.ch23.
From the Guest EditorsGoldberg SB, Herbst RS. From the Guest Editors The Cancer Journal 2015, 21: 365. PMID: 26389759, DOI: 10.1097/ppo.0000000000000152.
Lung-MAP--framework, overview, and design principles.Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Lung-MAP--framework, overview, and design principles. Chinese Clinical Oncology 2015, 4: 36. PMID: 26408303, DOI: 10.3978/j.issn.2304-3865.2015.09.02.
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic VulnerabilitiesSkoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities Cancer Discovery 2015, 5: 860-877. PMID: 26069186, PMCID: PMC4527963, DOI: 10.1158/2159-8290.cd-14-1236.
Abstract 1310: Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC)McLaughlin J, Schalper K, Carvajal-Hausdorf D, Pelekanou V, Velcheti V, Haack H, Silver M, Herbst R, LoRusso P, Rimm D. Abstract 1310: Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC) 2015, 1310-1310. DOI: 10.1158/1538-7445.am2015-1310.
Abstract 2094: GSK-3 is a novel target of CREB and GSK-3-CREB signaling participates in cell survival in lung cancerPark S, Lee J, Herbst R, Koo J. Abstract 2094: GSK-3 is a novel target of CREB and GSK-3-CREB signaling participates in cell survival in lung cancer 2015, 2094-2094. DOI: 10.1158/1538-7445.am2015-2094.
Abstract 3576: Rictor alterations elicit non-canonical signaling mechanisms contributing to tumorigenicity and therapeutic resistance in non-small cell lung cancer (NSCLC)Ruder D, Papadimitrakopoulou V, Shien K, Kalhor N, Lee J, Hong W, Tang X, Girard L, Minna J, Diao L, Wang J, Hanson N, Sun J, Miller V, Frampton G, Herbst R, Wistuba I, Izzo J. Abstract 3576: Rictor alterations elicit non-canonical signaling mechanisms contributing to tumorigenicity and therapeutic resistance in non-small cell lung cancer (NSCLC) 2015, 3576-3576. DOI: 10.1158/1538-7445.am2015-3576.
Abstract 745: Oncostatin M receptor activation leads to molecular targeted therapy resistance in non-small cell lung cancerShien K, Papadimitrakopoulou V, Ruder D, Hanson N, Kalhor N, Lee J, Hong W, Tang X, Herbst R, Girard L, Minna J, Kurie J, Wistuba I, Izzo J. Abstract 745: Oncostatin M receptor activation leads to molecular targeted therapy resistance in non-small cell lung cancer 2015, 745-745. DOI: 10.1158/1538-7445.am2015-745.
EGFR tyrosine kinase inhibitors in squamous cell lung cancerHirsch FR, Herbst RS, Gandara DR. EGFR tyrosine kinase inhibitors in squamous cell lung cancer The Lancet Oncology 2015, 16: 872-873. PMID: 26156654, DOI: 10.1016/s1470-2045(15)00126-6.
E2F8 as a Novel Therapeutic Target for Lung CancerPark SA, Platt J, Lee JW, López-Giráldez F, Herbst RS, Koo JS. E2F8 as a Novel Therapeutic Target for Lung Cancer Journal Of The National Cancer Institute 2015, 107 PMID: 26089541, PMCID: PMC4651101, DOI: 10.1093/jnci/djv151.
Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris A, Vortmeyer A, Jilaveanu L, Speaker S, Madura M, Rowen E, Gerrish H, Knapp-Perry E, Yao X, Chiang V, Kluger H. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. Journal Of Clinical Oncology 2015, 33: 8035-8035. DOI: 10.1200/jco.2015.33.15_suppl.8035.
Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Syrigos K, Herbst R, Rimm D. Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer. Journal Of Clinical Oncology 2015, 33: 3067-3067. DOI: 10.1200/jco.2015.33.15_suppl.3067.
Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.Horn L, Spigel D, Gettinger S, Antonia S, Gordon M, Herbst R, Sequist L, Chappey C, Kowanetz M, Sandler A, Soria J. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. Journal Of Clinical Oncology 2015, 33: 8029-8029. DOI: 10.1200/jco.2015.33.15_suppl.8029.
Lung Cancer in the Era of Precision MedicinePoliti K, Herbst RS. Lung Cancer in the Era of Precision Medicine Clinical Cancer Research 2015, 21: 2213-2220. PMID: 25979927, PMCID: PMC4505624, DOI: 10.1158/1078-0432.ccr-14-2748.
EGFR Mutations in Non–Small-Cell Lung Cancer: Find, Divide, and ConquerMorgensztern D, Politi K, Herbst RS. EGFR Mutations in Non–Small-Cell Lung Cancer: Find, Divide, and Conquer JAMA Oncology 2015, 1: 146-148. PMID: 26181013, DOI: 10.1001/jamaoncol.2014.278.
A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum StressLee JW, Park HS, Park SA, Ryu SH, Meng W, Jürgensmeier JM, Kurie JM, Hong WK, Boyer JL, Herbst RS, Koo JS. A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress PLOS ONE 2015, 10: e0122628. PMID: 25897662, PMCID: PMC4405579, DOI: 10.1371/journal.pone.0122628.
Innovative Clinical Trials: The LUNG‐MAP StudySteuer C, Papadimitrakopoulou V, Herbst R, Redman M, Hirsch F, Mack P, Ramalingam S, Gandara. Innovative Clinical Trials: The LUNG‐MAP Study Clinical Pharmacology & Therapeutics 2015, 97: 488-491. PMID: 25676724, DOI: 10.1002/cpt.88.
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 Clinical Cancer Research 2015, 21: 1514-1524. PMID: 25680375, PMCID: PMC4654466, DOI: 10.1158/1078-0432.ccr-13-3473.
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studiesPlatt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies BMC Cancer 2015, 15: 171. PMID: 25881079, PMCID: PMC4412099, DOI: 10.1186/s12885-015-1146-8.
Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung CancerSchalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL. Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer Journal Of The National Cancer Institute 2015, 107 PMID: 25650315, PMCID: PMC4565530, DOI: 10.1093/jnci/dju435.
Role of Chitinase 3–like-1 and Semaphorin 7a in Pulmonary Melanoma MetastasisMa B, Herzog EL, Lee CG, Peng X, Lee CM, Chen X, Rockwell S, Koo JS, Kluger H, Herbst RS, Sznol M, Elias JA. Role of Chitinase 3–like-1 and Semaphorin 7a in Pulmonary Melanoma Metastasis Cancer Research 2015, 75: 487-496. PMID: 25511377, PMCID: PMC4321965, DOI: 10.1158/0008-5472.can-13-3339.
Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical OncologyBrandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, Ostroff JS, Shields PG, Toll BA, Tyne CA, Viswanath K, Warren GW. Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology Clinical Cancer Research 2015, 21: 514-525. PMID: 25573384, DOI: 10.1158/1078-0432.ccr-14-2544.
Electronic Nicotine Delivery Systems: A Policy Statement From the American Association for Cancer Research and the American Society of Clinical OncologyBrandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, Ostroff JS, Shields PG, Toll BA, Tyne CA, Viswanath K, Warren GW. Electronic Nicotine Delivery Systems: A Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology Journal Of Clinical Oncology 2015, 33: 952-963. PMID: 25572671, DOI: 10.1200/jco.2014.59.4465.
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014 Journal Of Thoracic Oncology 2015, 10: s1-s63. PMID: 25535693, PMCID: PMC4346098, DOI: 10.1097/jto.0000000000000405.
48 Phase I Trials TodayMorgensztern D, LoRusso P, Boerner S, Herbst R, Eder J. 48 Phase I Trials Today 2015, 661-676.e2. DOI: 10.1016/b978-1-4557-4066-6.00048-2.
Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy DevelopmentGu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, Lee JJ. Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development Statistics In Biosciences 2014, 8: 99-128. PMID: 27617040, PMCID: PMC5014437, DOI: 10.1007/s12561-014-9124-2.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsHerbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 2014, 515: 563-567. PMID: 25428504, PMCID: PMC4836193, DOI: 10.1038/nature14011.
Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280AKowanetz M, Rabe C, Xiao Y, Wu Q, Koeppen H, Leddy C, Patel R, Powderly J, Kohrt H, Gettinger S, Soria J, Herbst R, Desai R, Denker M, Ruppel J, Boe M, Nakamura R, Fu L, Sumiyoshi T, Mokatrin A, Shen X, Fine G, Chen D, Hegde P. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A Journal For ImmunoTherapy Of Cancer 2014, 2: p136. PMCID: PMC4288453, DOI: 10.1186/2051-1426-2-s3-p136.
Emerging Science and Therapies in Non-small-Cell Lung Cancer: Targeting the MET PathwayKris MG, Arenberg DA, Herbst RS, Riely GJ. Emerging Science and Therapies in Non-small-Cell Lung Cancer: Targeting the MET Pathway Clinical Lung Cancer 2014, 15: 475. PMID: 25306384, DOI: 10.1016/j.cllc.2014.08.001.
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancerHenick BS, Herbst RS, Goldberg SB. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer Expert Opinion On Therapeutic Targets 2014, 18: 1407-1420. PMID: 25331677, DOI: 10.1517/14728222.2014.955794.
Abstract 985: The mutational landscape of LN metastasis and recurrence in HNSCCHedberg M, Goh G, Freilino M, Zeng Y, Lui V, Herbst R, Lifton R, Grandis J. Abstract 985: The mutational landscape of LN metastasis and recurrence in HNSCC 2014, 985-985. DOI: 10.1158/1538-7445.am2014-985.
Abstract 5049: Physician preferences in tobacco cessation support for cancer patients: A survey of physicians at National Cancer Institute Designated Cancer CentersPommerenke A, Alberg A, Brandon T, Croghan I, Cummings M, Dresler C, Gritz E, Herbst R, Leischow S, Marshall J, Toll B, Warren G. Abstract 5049: Physician preferences in tobacco cessation support for cancer patients: A survey of physicians at National Cancer Institute Designated Cancer Centers 2014, 5049-5049. DOI: 10.1158/1538-7445.am2014-5049.
New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial DesignsJürgensmeier JM, Eder JP, Herbst RS. New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs Clinical Cancer Research 2014, 20: 4425-4435. PMID: 25183480, PMCID: PMC5369358, DOI: 10.1158/1078-0432.ccr-13-0753.
“Companion Diagnostics”: Has Their Time Come and Gone?Hirsch FR, Bunn PA, Herbst RS. “Companion Diagnostics”: Has Their Time Come and Gone? Clinical Cancer Research 2014, 20: 4422-4424. PMID: 25059519, PMCID: PMC4155019, DOI: 10.1158/1078-0432.ccr-14-0932.
MEK Inhibition by Selumetinib Enhances the Antitumor and Anti-Metastatic Effects of Chemoradiation Therapy in Orthotopic Human Lung Cancer ModelsFurutani S, Komaki R, Smith P, Jürgensmeier J, Takahashi O, Rabin T, Herbst R, O'Reilly M. MEK Inhibition by Selumetinib Enhances the Antitumor and Anti-Metastatic Effects of Chemoradiation Therapy in Orthotopic Human Lung Cancer Models International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s796. DOI: 10.1016/j.ijrobp.2014.05.2300.
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung CancerVasan N, Boyer JL, Herbst RS. A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer Clinical Cancer Research 2014, 20: 3921-3930. PMID: 24893629, PMCID: PMC5369356, DOI: 10.1158/1078-0432.ccr-13-1762.
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancerHeymach JV, Lockwood SJ, Herbst RS, Johnson BE, Ryan AJ. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer Annals Of Oncology 2014, 25: 1941-1948. PMID: 25057173, PMCID: PMC4176452, DOI: 10.1093/annonc/mdu269.
B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung CancerGettinger S, Herbst RS. B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer The Cancer Journal 2014, 20: 281-289. PMID: 25098289, DOI: 10.1097/ppo.0000000000000063.
Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR -mutant lung adenocarcinoma.Goldberg S, Narayan A, Carriero N, Nemati R, Bommakanti A, Wurtz A, Boffa D, Decker R, Herbst R, Juergensmeier J, Politi K, Gettinger S, Patel A. Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR -mutant lung adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 8093-8093. DOI: 10.1200/jco.2014.32.15_suppl.8093.
BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC).Papadimitrakopoulou V, Lee J, Wistuba I, Tsao A, Fossella F, Heymach J, Kalhor N, Gupta S, Gettinger S, Byers L, Izzo J, Miller V, Diao L, Wang J, Wei C, Coombes K, Mauro D, Rubin E, Hong W, Herbst R. BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2014, 32: 8042-8042. DOI: 10.1200/jco.2014.32.15_suppl.8042.
A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.Arkenau H, Mateo J, Lemech C, Infante J, Burris H, Bang Y, Eder J, Herbst R, Sharma S, Chung H, Decordova S, Swales K, Garrett M, Loftiss J, Durante M, Russo M, Suttle B, Motwani M, Kumar R, De Bono J. A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors. Journal Of Clinical Oncology 2014, 32: 2514-2514. DOI: 10.1200/jco.2014.32.15_suppl.2514.
The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients.Tran H, Legendre B, Kim E, Blumenschein G, Tsao A, Herbst R, Wistuba I, Lewis M, Richardson K, Hong W, Heymach J. The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients. Journal Of Clinical Oncology 2014, 32: 8058-8058. DOI: 10.1200/jco.2014.32.15_suppl.8058.
Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC).McLaughlin J, Schalper K, Carvajal-Hausdorf D, Velcheti V, Haack H, Silver M, Goldberg S, Herbst R, Rimm D. Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2014, 32: 8064-8064. DOI: 10.1200/jco.2014.32.15_suppl.8064.
Clinical significance of TILs subtypes in non-small cell lung cancer.Schalper K, Brown J, McLaughlin J, Herbst R, Rimm D. Clinical significance of TILs subtypes in non-small cell lung cancer. Journal Of Clinical Oncology 2014, 32: 8082-8082. DOI: 10.1200/jco.2014.32.15_suppl.8082.
The KRAS -variant and treatment response in BATTLE-1.Weidhaas J, Kim E, Herbst R, Yu J, Slack F, Blumenschein G, Tsao A, Wistuba I, Lee J, Papadimitrakopoulou V, Hong W, Heymach J, Tran H. The KRAS -variant and treatment response in BATTLE-1. Journal Of Clinical Oncology 2014, 32: 8135-8135. DOI: 10.1200/jco.2014.32.15_suppl.8135.
Addressing findings from the 2014 Surgeon General’s Report: Physician preference for supporting tobacco cessation in cancer patients.Pommerenke A, Alberg A, Gritz E, Cummings K, Brandon T, Croghan I, Dresler C, Herbst R, Leischow S, Marshall J, Toll B, Warren G. Addressing findings from the 2014 Surgeon General’s Report: Physician preference for supporting tobacco cessation in cancer patients. Journal Of Clinical Oncology 2014, 32: e17508-e17508. DOI: 10.1200/jco.2014.32.15_suppl.e17508.
Standardizing measurement of tobacco use in cancer clinical trials.Land S, Toll B, Warren G, Brandon T, Mitchell S, Dresler C, Gritz E, Schnoll R, Sarna L, Moinpour C, Ostroff J, Khuri F, Buckner J, Cummings K, Herbst R, Shields P, Duffy S, Rigotti N, Prindiville S, Abrams J. Standardizing measurement of tobacco use in cancer clinical trials. Journal Of Clinical Oncology 2014, 32: e17658-e17658. DOI: 10.1200/jco.2014.32.15_suppl.e17658.
A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.Herbst R, Gurpide A, Surmont V, Kim D, Waqar S, Herder J, Lee D, Carcereny E, Reguart N, Wallmark J, Ramalingam S, Langer C, Lubiniecki G, Knowles J, Zhou H, Hanson M, Baas P. A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer. Journal Of Clinical Oncology 2014, 32: tps8124-tps8124. DOI: 10.1200/jco.2014.32.15_suppl.tps8124.
Vandetanib and Indwelling Pleural Catheter for Non–Small-Cell Lung Cancer With Recurrent Malignant Pleural EffusionMassarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Lee J, Hong WK, Herbst RS, Jimenez CA. Vandetanib and Indwelling Pleural Catheter for Non–Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion Clinical Lung Cancer 2014, 15: 379-386. PMID: 24913066, PMCID: PMC4160385, DOI: 10.1016/j.cllc.2014.04.002.
AACR Celebrates 50 Years of Tobacco Research and PolicyHerbst RS, Hobin JA, Gritz ER, Tobacco and Cancer W. AACR Celebrates 50 Years of Tobacco Research and Policy Clinical Cancer Research 2014, 20: 1709-1718. PMID: 24691637, DOI: 10.1158/1078-0432.ccr-14-0427.
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful OutcomesEllis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes Journal Of Clinical Oncology 2014, 32: 1277-1280. PMID: 24638016, DOI: 10.1200/jco.2013.53.8009.
Angiogenesis inhibition and lung-cancer therapyOnn A, Bar J, Herbst RS. Angiogenesis inhibition and lung-cancer therapy The Lancet Oncology 2014, 15: 124-125. PMID: 24480554, DOI: 10.1016/s1470-2045(14)70010-5.
“Quitting Smoking Will Benefit Your Health”: The Evolution of Clinician Messaging to Encourage Tobacco CessationToll BA, Rojewski AM, Duncan LR, Latimer-Cheung AE, Fucito LM, Boyer JL, O'Malley SS, Salovey P, Herbst RS. “Quitting Smoking Will Benefit Your Health”: The Evolution of Clinician Messaging to Encourage Tobacco Cessation Clinical Cancer Research 2014, 20: 301-309. PMID: 24436474, PMCID: PMC3927319, DOI: 10.1158/1078-0432.ccr-13-2261.
Abstract B04: Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms.Lee J, Park H, Park S, Herbst R, Koo J. Abstract B04: Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms. Clinical Cancer Research 2014, 20: b04-b04. DOI: 10.1158/1078-0432.14aacriaslc-b04.
Abstract PR03: Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms.Lee J, Park H, Park S, Herbst R, Koo J. Abstract PR03: Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms. Clinical Cancer Research 2014, 20: pr03-pr03. DOI: 10.1158/1078-0432.14aacriaslc-pr03.
Tyrosine-kinase inhibitors in oncologyTsao A, Papadimitrakopoulou V, Herbst R. Tyrosine-kinase inhibitors in oncology 2013, 872-883. DOI: 10.1017/cbo9781139046947.083.
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2013, 19: 6967-75. PMID: 24166906, PMCID: PMC3905243, DOI: 10.1158/1078-0432.CCR-12-1818.
Reducing Tobacco‐Related Cancer Incidence and Mortality: Summary of an Institute of Medicine WorkshopBalogh EP, Dresler C, Fleury ME, Gritz ER, Kean TJ, Myers ML, Nass SJ, Nevidjon B, Toll BA, Warren GW, Herbst RS. Reducing Tobacco‐Related Cancer Incidence and Mortality: Summary of an Institute of Medicine Workshop The Oncologist 2013, 19: 21-31. PMID: 24304712, PMCID: PMC3903060, DOI: 10.1634/theoncologist.2013-0230.
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536 Journal Of Thoracic Oncology 2013, 8: 1519-1528. PMID: 24189513, PMCID: PMC4072123, DOI: 10.1097/jto.0000000000000009.
Programmed death ligand-1 expression in non-small cell lung cancerVelcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer Laboratory Investigation 2013, 94: 107-116. PMID: 24217091, PMCID: PMC6125250, DOI: 10.1038/labinvest.2013.130.
IS7–2 Personalized Therapy for Advanced Non-Small Cell Lung Cancer: From the Battle Trial to Master ProtocolsHerbst R. IS7–2 Personalized Therapy for Advanced Non-Small Cell Lung Cancer: From the Battle Trial to Master Protocols Annals Of Oncology 2013, 24: ix19. DOI: 10.1093/annonc/mdt447.2.
Addressing Tobacco Use in Patients With Cancer: A Survey of American Society of Clinical Oncology MembersWarren GW, Marshall JR, Cummings KM, Toll BA, Gritz ER, Hutson A, Dibaj S, Herbst R, Mulshine JL, Hanna N, Dresler CA. Addressing Tobacco Use in Patients With Cancer: A Survey of American Society of Clinical Oncology Members JCO Oncology Practice 2013, 9: 258-262. PMID: 23943904, PMCID: PMC3770508, DOI: 10.1200/jop.2013.001025.
BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).Papadimitrakopoulou V, Wistuba I, Lee J, Tsao A, Kalhor N, Fossella F, Heymach J, Alden C, Gettinger S, Coombes K, Saintigny P, Tang X, Duffield E, Boyer J, Davis S, Powis G, Mauro D, Rubin E, Hong W, Herbst R. BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: tps8118-tps8118. DOI: 10.1200/jco.2013.31.15_suppl.tps8118.
Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC).Velcheti V, Schalper K, Carvajal D, Chen L, Sznol M, Gettinger S, Herbst R, Rimm D. Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: 11075-11075. DOI: 10.1200/jco.2013.31.15_suppl.11075.
Addressing tobacco use and cessation in cancer patients: Practices, perceptions, and barriers reported by oncology providers.Warren G, Marshall J, Cummings K, Toll B, Gritz E, Hutson A, Dibaj S, Herbst R, Mulshine J, Hanna N, Dresler C. Addressing tobacco use and cessation in cancer patients: Practices, perceptions, and barriers reported by oncology providers. Journal Of Clinical Oncology 2013, 31: 1561-1561. DOI: 10.1200/jco.2013.31.15_suppl.1561.
A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.Herbst R, Gordon M, Fine G, Sosman J, Soria J, Hamid O, Powderly J, Burris H, Mokatrin A, Kowanetz M, Leabman M, Anderson M, Chen D, Hodi F. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Journal Of Clinical Oncology 2013, 31: 3000-3000. DOI: 10.1200/jco.2013.31.15_suppl.3000.
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).Spigel D, Gettinger S, Horn L, Herbst R, Gandhi L, Gordon M, Cruz C, Conkling P, Cassier P, Antonia S, Burris H, Fine G, Mokatrin A, Kowanetz M, Shen X, Chen D, Soria J. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: 8008-8008. DOI: 10.1200/jco.2013.31.15_suppl.8008.
Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials.Platt A, Elvin P, Morten J, Ji Q, Donald E, Womack C, Su X, Zheng L, Gladwin A, Vasselli J, Lee J, De Boer R, Herbst R. Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials. Journal Of Clinical Oncology 2013, 31: 8045-8045. DOI: 10.1200/jco.2013.31.15_suppl.8045.
Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer PatientsWarren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hutson A, Dibaj S, Herbst R, Dresler C, Committee I. Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients Journal Of Thoracic Oncology 2013, 8: 543-548. PMID: 23529191, PMCID: PMC3628367, DOI: 10.1097/jto.0b013e318288dc96.
Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE TrialTsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial Journal Of Thoracic Oncology 2013, 8: 658-661. PMID: 23584298, PMCID: PMC5118909, DOI: 10.1097/jto.0b013e31828d08ae.
Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy StatementToll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS, Tobacco and Cancer W. Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement Clinical Cancer Research 2013, 19: 1941-1948. PMID: 23570694, PMCID: PMC5992896, DOI: 10.1158/1078-0432.ccr-13-0666.
Abstract 4382: Genome-Wide Gene Expression analysis and molecular portraits regulated by NASEp, an inhibitor of CREB and CBP interaction, in non-small cell lung cancer.Park S, Platt J, Park H, Lee J, Stern D, Herbst R, Koo J. Abstract 4382: Genome-Wide Gene Expression analysis and molecular portraits regulated by NASEp, an inhibitor of CREB and CBP interaction, in non-small cell lung cancer. Cancer Research 2013, 73: 4382-4382. DOI: 10.1158/1538-7445.am2013-4382.
Abstract 1042: Maintenance or switch maintenance therapy with selumetinib or cediranib after chemoradiation prolongs survival in an orthotopic human lung cancer model.Takahashi O, Komaki R, Jürgensmeier J, Smith P, Wistuba I, Tailor R, Jacoby J, Korshunova M, Kim Y, Erez B, Herbst R, O'Reilly M. Abstract 1042: Maintenance or switch maintenance therapy with selumetinib or cediranib after chemoradiation prolongs survival in an orthotopic human lung cancer model. Cancer Research 2013, 73: 1042-1042. DOI: 10.1158/1538-7445.am2013-1042.
Abstract 2878: Targeting the CXCL5-CXCR2-CREB signaling axis suppresses growth, survival, and invasion of lung adenocarcinoma.Park H, Lee J, Saintigny P, Kurie J, Herbst R, Koo J. Abstract 2878: Targeting the CXCL5-CXCR2-CREB signaling axis suppresses growth, survival, and invasion of lung adenocarcinoma. Cancer Research 2013, 73: 2878-2878. DOI: 10.1158/1538-7445.am2013-2878.
Abstract 3414: Disruption of CREB-CREBBP association by 2-Naphthol AS-E phosphate induces cell cycle arrest and apoptosis in non-small cell lung cancer cells .Lee J, Park H, Ryu S, Koch P, Boyer J, Morgensztern D, Herbst R, Koo J. Abstract 3414: Disruption of CREB-CREBBP association by 2-Naphthol AS-E phosphate induces cell cycle arrest and apoptosis in non-small cell lung cancer cells . Cancer Research 2013, 73: 3414-3414. DOI: 10.1158/1538-7445.am2013-3414.
Abstract 3938: Role of Chi3l1/YKL-40 in the tumor progression and metastasis in the lung.Lee C, Ma B, Koo J, Herbst R, Elias J. Abstract 3938: Role of Chi3l1/YKL-40 in the tumor progression and metastasis in the lung. Cancer Research 2013, 73: 3938-3938. DOI: 10.1158/1538-7445.am2013-3938.
Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumoursSoria JC, Baselga J, Hanna N, Laurie SA, Bahleda R, Felip E, Calvo E, Armand JP, Shepherd FA, Harbison CT, Berman D, Park JS, Zhang S, Vakkalagadda B, Kurland JF, Pathak AK, Herbst RS. Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours European Journal Of Cancer 2013, 49: 1815-1824. PMID: 23490650, DOI: 10.1016/j.ejca.2013.02.012.
Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinomaCai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma Cancer Cytopathology 2013, 121: 500-507. PMID: 23495083, DOI: 10.1002/cncy.21288.
Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer CellsYamaguchi H, Hsu JL, Chen CT, Wang YN, Hsu MC, Chang SS, Du Y, Ko HW, Herbst R, Hung MC. Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells Clinical Cancer Research 2013, 19: 845-854. PMID: 23344263, PMCID: PMC3703145, DOI: 10.1158/1078-0432.ccr-12-2621.
Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung CancerIsobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS. Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer Journal Of Thoracic Oncology 2013, 8: 140-146. PMID: 23328546, DOI: 10.1097/jto.0b013e3182725ff9.
CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung AdenocarcinomaSaintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Soto L, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma Cancer Research 2013, 73: 571-582. PMID: 23204236, PMCID: PMC3548940, DOI: 10.1158/0008-5472.can-12-0263.
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2013, 19: 279-90. PMID: 23091115, PMCID: PMC3567921, DOI: 10.1158/1078-0432.CCR-12-1558.
Personalized therapy.Ujhazy P, Herbst R. Personalized therapy. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2012, 7: S401-3. PMID: 23160334, DOI: 10.1097/JTO.0b013e31826df27c.
Miscellaneous AgentsMorgensztern D, Herbst RS. Miscellaneous Agents Journal Of Thoracic Oncology 2012, 7: s390-s391. PMID: 23160329, DOI: 10.1097/jto.0b013e31826df1d2.
A step towards treating KRAS-mutant NSCLCGoldberg SB, Schlessinger J, Boyer JL, Herbst RS. A step towards treating KRAS-mutant NSCLC The Lancet Oncology 2012, 14: 3-5. PMID: 23200176, DOI: 10.1016/s1470-2045(12)70528-4.
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2012, 7: 1645-52. PMID: 23059780, PMCID: PMC5161038, DOI: 10.1097/JTO.0b013e31826910ff.
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) AgonistSubbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist Molecular Cancer Therapeutics 2012, 11: 2541-2546. PMID: 22914439, PMCID: PMC3496030, DOI: 10.1158/1535-7163.mct-12-0358.
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumoursMartin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours British Journal Of Cancer 2012, 107: 1268-1276. PMID: 22996612, PMCID: PMC3494424, DOI: 10.1038/bjc.2012.407.
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumoursKozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, De Castro Carpeño J, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours British Journal Of Cancer 2012, 107: 1277-1285. PMID: 22990652, PMCID: PMC3494447, DOI: 10.1038/bjc.2012.406.
The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care.Bosserman L, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, Raptis A, Hallquist A, Perree M, Rajurkar S, Karimi M, Rogers K, Davidson D, Willis C, Penalver M, Homesley H, Burrell M, Garrett A, Rutledge J, Chernick M, Presant CA. The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care. Cancer Research 2012, 72: 3901-5. PMID: 22865459, DOI: 10.1158/0008-5472.CAN-12-0681.
Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR. Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819 Clinical Cancer Research 2012, 18: 4004-4012. PMID: 22592956, PMCID: PMC3409929, DOI: 10.1158/1078-0432.ccr-12-0167.
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid TumorsHong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors Clinical Cancer Research 2012, 18: 4173-4182. PMID: 22693357, DOI: 10.1158/1078-0432.ccr-12-0714.
Multitargeted Tyrosine Kinase Inhibitors in Unselected Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC): Impressions From MONET (the Motesanib NSCLC Efficacy and Tolerability Study)Morgensztern D, Herbst RS. Multitargeted Tyrosine Kinase Inhibitors in Unselected Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC): Impressions From MONET (the Motesanib NSCLC Efficacy and Tolerability Study) Journal Of Clinical Oncology 2012, 30: 2805-2808. PMID: 22753916, DOI: 10.1200/jco.2012.42.7260.
Tobacco Assessment in Actively Accruing National Cancer Institute Cooperative Group Program Clinical TrialsPeters EN, Torres E, Toll BA, Cummings KM, Gritz ER, Hyland A, Herbst RS, Marshall JR, Warren GW. Tobacco Assessment in Actively Accruing National Cancer Institute Cooperative Group Program Clinical Trials Journal Of Clinical Oncology 2012, 30: 2869-2875. PMID: 22689794, PMCID: PMC3410402, DOI: 10.1200/jco.2011.40.8815.
L4.1 Evolution of Battle Trials at Md Anderson Cancer CenterHong W, Kim E, Herbst R, Papadimitrakopoulou V, Gold K, Wistuba I, Lee J, Lippman S. L4.1 Evolution of Battle Trials at Md Anderson Cancer Center Annals Of Oncology 2012, 23: v7. DOI: 10.1016/s0923-7534(20)31272-2.
Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx.Acevedo-Gadea C, Baumgart M, Wang Z, Deshpande H, Davies M, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2012, 30: 5529-5529. DOI: 10.1200/jco.2012.30.15_suppl.5529.
Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck.Baumgart M, Acevedo-Gadea C, Wang Z, Buta E, Davies M, Deshpande H, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2012, 30: 5532-5532. DOI: 10.1200/jco.2012.30.15_suppl.5532.
Abstract 5605: LKB1 and KRAS mutations predict resistance to PI3K/Akt inhibitors in non-small cell lung cancerByers L, Diao L, Wang J, Girard L, Peyton M, Gazdar A, Groth P, Paul J, Liu N, Kim E, Mauro D, Herbst R, Papadimitrakopoulou V, Coombes K, Weinstein J, Minna J, Heymach J. Abstract 5605: LKB1 and KRAS mutations predict resistance to PI3K/Akt inhibitors in non-small cell lung cancer Cancer Research 2012, 72: 5605-5605. DOI: 10.1158/1538-7445.am2012-5605.
Abstract 648: Tobacco assessment in actively accruing Cooperative Group clinical trialsWarren G, Peters E, Torres E, Cummings K, Gritz E, Hyland A, Herbst R, Marshall J, Toll B. Abstract 648: Tobacco assessment in actively accruing Cooperative Group clinical trials Cancer Research 2012, 72: 648-648. DOI: 10.1158/1538-7445.am2012-648.
Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and MetastasisTakahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis Clinical Cancer Research 2012, 18: 1641-1654. PMID: 22275507, PMCID: PMC3306446, DOI: 10.1158/1078-0432.ccr-11-2324.
Targeting Vascular Endothelial Growth Factor in Patients With Squamous Cell Lung CancerKoo PJ, Morgensztern D, Boyer JL, Herbst RS. Targeting Vascular Endothelial Growth Factor in Patients With Squamous Cell Lung Cancer Journal Of Clinical Oncology 2012, 30: 1137-1139. PMID: 22355057, DOI: 10.1200/jco.2011.40.4053.
Abstract A12: High-throughput mutation analysis of NSCLC circulating tumor cellsErickson H, Hanson N, Tran H, Mills G, Kim E, Heymach J, Wistuba I, Galindo H, Stemke-Hale K, Giri U, McDowell C, Girard L, Lee J, Herbst R, Minna J, Bischoff F. Abstract A12: High-throughput mutation analysis of NSCLC circulating tumor cells Clinical Cancer Research 2012, 18: a12-a12. DOI: 10.1158/1078-0432.12aacriaslc-a12.
Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy TrialsBerry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials Clinical Cancer Research 2012, 18: 638-644. PMID: 22298897, PMCID: PMC4314693, DOI: 10.1158/1078-0432.ccr-11-2018.
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical OutcomeIhle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome Journal Of The National Cancer Institute 2012, 104: 228-239. PMID: 22247021, PMCID: PMC3274509, DOI: 10.1093/jnci/djr523.
EGFR expression and the flexibility of FLEXHirsch FR, Herbst RS. EGFR expression and the flexibility of FLEX The Lancet Oncology 2011, 13: 3-5. PMID: 22056020, DOI: 10.1016/s1470-2045(11)70316-3.
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumoursPan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, Herbst RS, Eckhardt SG, Holland PM. Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours British Journal Of Cancer 2011, 105: 1830-1838. PMID: 22033270, PMCID: PMC3251880, DOI: 10.1038/bjc.2011.456.
Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment Over 15 YearsGaspar LE, McNamara EJ, Gay EG, Putnam JB, Crawford J, Herbst RS, Bonner JA. Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment Over 15 Years Clinical Lung Cancer 2011, 13: 115-122. PMID: 22000695, DOI: 10.1016/j.cllc.2011.05.008.
Predictive Factors Of Long-term Five Years Overall Survival Among Patients With Limited Small Cell Lung Cancer Treated With Radiation Treatment And Chemotherapy By Treatment Time PeriodsWei X, Allen P, O'Reilly M, Fossella F, Liao Z, Heymach J, Herbst R, Chang J, Cox J, Komaki R. Predictive Factors Of Long-term Five Years Overall Survival Among Patients With Limited Small Cell Lung Cancer Treated With Radiation Treatment And Chemotherapy By Treatment Time Periods International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s588. DOI: 10.1016/j.ijrobp.2011.06.1102.
Highlights in NSCLC From the IASLC (International Association for the Study of Lung Cancer) 14th World Conference on Lung Cancer.Herbst RS. Highlights in NSCLC From the IASLC (International Association for the Study of Lung Cancer) 14th World Conference on Lung Cancer. Clinical Advances In Hematology And Oncology 2011, 9: 1-24. PMID: 22362179.
Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant ChemotherapyYang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy Cancer Research 2011, 71: 5512-5521. PMID: 21724587, PMCID: PMC3159530, DOI: 10.1158/0008-5472.can-10-2614.
An Open-Label, Multicenter, Three-Stage, Phase II Study of S-1 in Combination with Cisplatin as First-Line Therapy for Patients with Advanced Non-small Cell Lung CancerSandler A, Graham C, Baggstrom M, Herbst R, Zergebel C, Saito K, Jones D. An Open-Label, Multicenter, Three-Stage, Phase II Study of S-1 in Combination with Cisplatin as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer Journal Of Thoracic Oncology 2011, 6: 1400-1406. PMID: 21673602, DOI: 10.1097/jto.0b013e31820d7805.
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumorsInfante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors Cancer Chemotherapy And Pharmacology 2011, 69: 165-172. PMID: 21638123, DOI: 10.1007/s00280-011-1667-z.
The BATTLE Trial: Personalizing Therapy for Lung CancerKim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer Cancer Discovery 2011, 1: 44-53. PMID: 22586319, PMCID: PMC4211116, DOI: 10.1158/2159-8274.cd-10-0010.
Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors.Soulieres D, Wolf J, Shepherd F, Cappuzzo F, Bunn P, Herbst R, Hirsch F, Kerr K, Mitsudomi T, Tsao M, Yang C, Richardson F, Klughammer B, Wacker B, Sternberg D, Davies A. Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. Journal Of Clinical Oncology 2011, 29: 7533-7533. DOI: 10.1200/jco.2011.29.15_suppl.7533.
Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial.Tsao A, Liu S, Lee J, Alden C, Kim E, Blumenschein G, Herbst R, Lippman S, Wistuba I, Hong W. Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial. Journal Of Clinical Oncology 2011, 29: 7550-7550. DOI: 10.1200/jco.2011.29.15_suppl.7550.
Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324 Journal Of Clinical Oncology 2011, 29: 2312-2318. PMID: 21555682, PMCID: PMC3107747, DOI: 10.1200/jco.2010.31.7875.
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trialHerbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial The Lancet 2011, 377: 1846-1854. PMID: 21621716, PMCID: PMC4134127, DOI: 10.1016/s0140-6736(11)60545-x.
Abstract 3269: VEGF inhibitor resistance is associated with stromal EGFR activation and normalized revascularization in an orthotopic model of lung adenocarcinomaCascone T, Saigal B, Reynolds D, Erez B, Jacoby J, Nilsson M, Lin H, Herbst R, Langley R, Heymach J. Abstract 3269: VEGF inhibitor resistance is associated with stromal EGFR activation and normalized revascularization in an orthotopic model of lung adenocarcinoma Cancer Research 2011, 71: 3269-3269. DOI: 10.1158/1538-7445.am2011-3269.
Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRASSaintigny P, Diao L, Wang J, Girard L, Lin S, Coombes K, Liu S, Lee J, Weinstein J, Xie Y, Fan Y, Tang X, Kim E, Herbst R, Tsao A, Blumenschein G, Mao L, Lippman S, Minna J, Hong W, Wistuba I, Heymach J. Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS Cancer Research 2011, 71: 4109-4109. DOI: 10.1158/1538-7445.am2011-4109.
Abstract 5166: Identification of prostate stem cell antigen (PSCA) as a potential marker for lung cancer brain metastasisGalindo H, Suraokar M, Behrens C, Woods D, Kalhor N, Aldape K, Fujimoto J, Herbst R, Erickson H, Wistuba I. Abstract 5166: Identification of prostate stem cell antigen (PSCA) as a potential marker for lung cancer brain metastasis Cancer Research 2011, 71: 5166-5166. DOI: 10.1158/1538-7445.am2011-5166.
Abstract 629: MEK inhibition by selumetinib (AZD6244) inhibits progression with a multicentric antiangiogenic effect and enhances the efficacy of cediranib in orthotopic human lung cancer modelsTakahashi O, Komaki R, Smith P, Jürgensmeier J, Ryan A, Bekele B, Wistuba I, Jacoby J, Korshunova M, Biernacka A, Erez B, Hosho K, Herbst R, O'Reilly M. Abstract 629: MEK inhibition by selumetinib (AZD6244) inhibits progression with a multicentric antiangiogenic effect and enhances the efficacy of cediranib in orthotopic human lung cancer models Cancer Research 2011, 71: 629-629. DOI: 10.1158/1538-7445.am2011-629.
Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancerIhle N, Herbst R, Kim E, Wistuba I, Lee J, Blumenschein G, Tsao A, Chen L, Zhang S, Alden C, Tang X, Liu S, Stewart D, Papadimitrakopoulou V, Heymach J, Tran H, Hicks M, Erasmus J, Gupta S, Minna J, Larsen J, Lippman S, Hong W, Powis G. Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer Cancer Research 2011, 71: 955-955. DOI: 10.1158/1538-7445.am2011-955.
Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination)Heymach J, Saintigny P, Kim E, Byers L, Lee J, Coombes K, Diao L, Wang J, Tran H, Fan Y, Tsao A, Blumenschein G, Papadimitrakopoulou V, Tang X, Story M, Xie Y, Girard L, Weinstein J, Mao L, Minna J, Herbst R, Lippman S, Hong W, Wistuba I. Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) Cancer Research 2011, 71: lb-88-lb-88. DOI: 10.1158/1538-7445.am2011-lb-88.
Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung CancerGovindan R, Morgensztern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, Saito K, Zergebel C, Schiller J. Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer Journal Of Thoracic Oncology 2011, 6: 790-795. PMID: 21325974, DOI: 10.1097/jto.0b013e3182103b51.
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinomaCascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma Journal Of Clinical Investigation 2011, 121: 1313-1328. PMID: 21436589, PMCID: PMC3070607, DOI: 10.1172/jci42405.
Methodological and practical challenges for personalized cancer therapiesWistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies Nature Reviews Clinical Oncology 2011, 8: 135-141. PMID: 21364686, DOI: 10.1038/nrclinonc.2011.2.
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid TumorsHerbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM. A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors Clinical Cancer Research 2010, 16: 5883-5891. PMID: 20947515, DOI: 10.1158/1078-0432.ccr-10-0631.
Future directions of monoclonal antibody use in personalized lung cancer therapy.Chu CT, Jacoby JJ, Herbst RS. Future directions of monoclonal antibody use in personalized lung cancer therapy. Oncology 2010, 24: 1226-8. PMID: 21192563.
Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In VivoMeng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo PLOS ONE 2010, 5: e14124. PMID: 21124782, PMCID: PMC2993951, DOI: 10.1371/journal.pone.0014124.
366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of PI3 kinaseJimeno A, Herbst R, Falchook G, Messersmith W, Camidge D, Peterson S, Hausman D, Kurzrock R, Eckhardt S, Hong D. 366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase European Journal Of Cancer Supplements 2010, 8: 116. DOI: 10.1016/s1359-6349(10)72073-5.
The Advantage of using PET SUV to Evaluate Tumor Response by RECIST Criteria in Patients with Stage IIIA/B Non-small Cell Lung Cancer (NSCLC) after Concurrent Chemotherapy and Tarceva with RadiotherapyWei X, Allen P, Blumenschein G, Hong W, Herbst R, O'Reily M, Heymach J, Erasmus J, Lee J, Komaki R. The Advantage of using PET SUV to Evaluate Tumor Response by RECIST Criteria in Patients with Stage IIIA/B Non-small Cell Lung Cancer (NSCLC) after Concurrent Chemotherapy and Tarceva with Radiotherapy International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s498. DOI: 10.1016/j.ijrobp.2010.07.1165.
Predictive Implications of KRAS and EGFR Gene Mutations in Non-small Cell Lung Cancer Treated with Radiation TherapyLikhacheva A, Thomas J, Kim E, Allen P, Komaki R, Cox J, Herbst R, Welsh J. Predictive Implications of KRAS and EGFR Gene Mutations in Non-small Cell Lung Cancer Treated with Radiation Therapy International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s128-s129. DOI: 10.1016/j.ijrobp.2010.07.323.
Opening Up to Precompetitive CollaborationAltshuler JS, Balogh E, Barker AD, Eck SL, Friend SH, Ginsburg GS, Herbst RS, Nass SJ, Streeter CM, Wagner JA. Opening Up to Precompetitive Collaboration Science Translational Medicine 2010, 2: 52cm26. PMID: 20926831, DOI: 10.1126/scitranslmed.3001515.
Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342 Journal Of Clinical Oncology 2010, 28: 4747-4754. PMID: 20921467, PMCID: PMC3020704, DOI: 10.1200/jco.2009.27.9356.
Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate samplingZoog SJ, Y. C, Kaplan‐Lefko P, Hawkins JM, Moriguchi J, Zhou L, Pan Y, Hsu C, Friberg G, Herbst R, Hill J, Juan G. Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling Cytometry Part A 2010, 77A: 849-860. PMID: 20623688, DOI: 10.1002/cyto.a.20940.
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialHerbst RS, Sun Y, Eberhardt W, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial The Lancet Oncology 2010, 11: 619-626. PMID: 20570559, PMCID: PMC3225192, DOI: 10.1016/s1470-2045(10)70132-7.
Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in MiceJacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, Herbst RS. Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice Journal Of Thoracic Oncology 2010, 5: 940-949. PMID: 20512076, PMCID: PMC3782111, DOI: 10.1097/jto.0b013e3181dc211f.
A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the LungLeighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS. A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung Journal Of Thoracic Oncology 2010, 5: 1054-1059. PMID: 20593550, DOI: 10.1097/jto.0b013e3181e2f7fb.
Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III TrialLu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial Journal Of The National Cancer Institute 2010, 102: 859-865. PMID: 20505152, PMCID: PMC2902826, DOI: 10.1093/jnci/djq179.
Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and TherapyHaura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy Journal Of Thoracic Oncology 2010, 5: s207-s213. PMID: 20502275, DOI: 10.1097/jto.0b013e3181e2f682.
First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.Burris H, Rodon J, Sharma S, Herbst R, Tabernero J, Infante J, Silva A, Demanse D, Hackl W, Baselga J. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2010, 28: 3005-3005. DOI: 10.1200/jco.2010.28.15_suppl.3005.
Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.Tibes R, Falchook G, Von Hoff D, Weiss G, Iyengar T, Kurzrock R, Pestano L, Lowe A, Herbst R. Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α. Journal Of Clinical Oncology 2010, 28: 3076-3076. DOI: 10.1200/jco.2010.28.15_suppl.3076.
Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.Jimeno A, Herbst R, Falchook G, Messersmith W, Hecker S, Peterson S, Hausman D, Kurzrock R, Eckhardt S, Hong D. Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. Journal Of Clinical Oncology 2010, 28: 3089-3089. DOI: 10.1200/jco.2010.28.15_suppl.3089.
Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.Johnson B, Ryan A, Heymach J, Stephens C, Kennedy S, Langmuir P, Herbst R. Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC. Journal Of Clinical Oncology 2010, 28: 7516-7516. DOI: 10.1200/jco.2010.28.15_suppl.7516.
Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.Herbst R, Blumenschein G, Kim E, Lee J, Tsao A, Alden C, Liu S, Stewart D, Wistuba I, Hong W. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. Journal Of Clinical Oncology 2010, 28: 7609-7609. DOI: 10.1200/jco.2010.28.15_suppl.7609.
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced CancerHerbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer Journal Of Clinical Oncology 2010, 28: 2839-2846. PMID: 20458040, DOI: 10.1200/jco.2009.25.1991.
Tobacco and Cancer: An American Association for Cancer Research Policy StatementViswanath K, Herbst RS, Land SR, Leischow SJ, Shields PG, Tobacco and Cancer W. Tobacco and Cancer: An American Association for Cancer Research Policy Statement Cancer Research 2010, 70: 3419-3430. PMID: 20388799, DOI: 10.1158/0008-5472.can-10-1087.
Abstract 1397: VEGFR signaling inhibition by cediranib enhances the antitumor and anti-metastatic effects of chemotherapy and radiation in an orthotopic human lung cancer modelTakahashi O, Komaki R, Tailor R, Jürgensmeier J, Ryan A, Smith P, Jacoby J, Hosho K, Korshunova M, Erez B, Herbst R, O'Reilly M. Abstract 1397: VEGFR signaling inhibition by cediranib enhances the antitumor and anti-metastatic effects of chemotherapy and radiation in an orthotopic human lung cancer model Cancer Research 2010, 70: 1397-1397. DOI: 10.1158/1538-7445.am10-1397.
Abstract 1981: MYC downregulation and chemoresistance in non-small cell lung cancer (NSCLC): Evidence from the Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) programSaintigny P, Byers L, Zhang L, Yordy J, Tang X, Girard L, Lang W, Fan Y, Ji L, Lee J, Kim E, Hong W, Lippman S, Herbst R, Minna J, Wistuba I, Heymach J, Mao L. Abstract 1981: MYC downregulation and chemoresistance in non-small cell lung cancer (NSCLC): Evidence from the Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program Cancer Research 2010, 70: 1981-1981. DOI: 10.1158/1538-7445.am10-1981.
Abstract 306: KRas mediated induction of HIF-1α in normoxia promotes tumorigenesis and identifies HIF-1α as a therapeutic targetIhle N, Kingston J, Gumbiner-Russo L, Byers L, Yordy J, Giri U, Heymach J, Minna J, Larsen J, Herbst R, Garth P. Abstract 306: KRas mediated induction of HIF-1α in normoxia promotes tumorigenesis and identifies HIF-1α as a therapeutic target Cancer Research 2010, 70: 306-306. DOI: 10.1158/1538-7445.am10-306.
Abstract 3435: VEGF or VEGF and EGF receptor signaling inhibition by cediranib or vandetanib enhances the therapeutic effects of chemoradiation in an orthotopic small cell lung cancer modelHosho K, Komaki R, Tailor R, Ryan A, Jürgensmeier J, Smith P, Jacoby J, Takahashi O, Korshunova M, Erez B, Herbst R, O'Reilly M. Abstract 3435: VEGF or VEGF and EGF receptor signaling inhibition by cediranib or vandetanib enhances the therapeutic effects of chemoradiation in an orthotopic small cell lung cancer model Cancer Research 2010, 70: 3435-3435. DOI: 10.1158/1538-7445.am10-3435.
Abstract 3632: Addition of the HIF-1α inhibitor PX-478 enhances the therapeutic efficacy of EGFR inhibitors in an orthotopic human lung adenocarcinoma modelJacoby J, Erez B, Takahashi O, Korshunova M, Hosho K, Powis G, O'Reilly M, Herbst R. Abstract 3632: Addition of the HIF-1α inhibitor PX-478 enhances the therapeutic efficacy of EGFR inhibitors in an orthotopic human lung adenocarcinoma model Cancer Research 2010, 70: 3632-3632. DOI: 10.1158/1538-7445.am10-3632.
Abstract 794: Targeted-therapy related molecular biomarker characterization in NSCLC smokers and never-smokers by a novel qRT-PCR for microdissected tissues methodologyYan W, Shih J, Raso M, Rodriguez-Canales J, Behrens C, Papadimitrakopoulou V, Herbst R, Emmert-Buck M, Wistuba I, Erickson H. Abstract 794: Targeted-therapy related molecular biomarker characterization in NSCLC smokers and never-smokers by a novel qRT-PCR for microdissected tissues methodology Cancer Research 2010, 70: 794-794. DOI: 10.1158/1538-7445.am10-794.
Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line TherapyWilliam WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy American Journal Of Clinical Oncology 2010, 33: 148-152. PMID: 19687727, PMCID: PMC5118944, DOI: 10.1097/coc.0b013e318199fb99.
BATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination)Hong W, Herbst R, Kim E. BATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination) 2010 DOI: 10.21236/ada542458.
Evolving Treatment Algorithms for Advanced Non–Small-Cell Lung Cancer: 2009 Looking Toward 2012GANDARA DR, MACK PC, Tianhong L, LARA PN, HERBST RS, 杨永. Evolving Treatment Algorithms for Advanced Non–Small-Cell Lung Cancer: 2009 Looking Toward 2012 Chinese Journal Of Lung Cancer 2010, 13: 238-241. PMID: 20681067, PMCID: PMC6136060, DOI: 10.3779/j.issn.1009-3419.2010.03.16.
Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. Clinical Lung Cancer 2010, 11: 126-31. PMID: 20199979, DOI: 10.3816/CLC.2010.n.017.
Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain InhibitorMeuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G. Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor Molecular Cancer Therapeutics 2010, 9: 706-717. PMID: 20197390, PMCID: PMC2837366, DOI: 10.1158/1535-7163.mct-09-0985.
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced MalignanciesCamidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D. A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies Clinical Cancer Research 2010, 16: 1256-1263. PMID: 20145186, DOI: 10.1158/1078-0432.ccr-09-1267.
IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative Treatments and Therapeutic Modalities)Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative Treatments and Therapeutic Modalities) 2010 DOI: 10.21236/ada525846.
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC) Investigational New Drugs 2010, 29: 499-505. PMID: 20094773, DOI: 10.1007/s10637-009-9380-z.
Future directions in multimodality therapy for NSCLCTsao AS, Roth JA, Herbst RS. Future directions in multimodality therapy for NSCLC Nature Reviews Clinical Oncology 2010, 7: 10-12. PMID: 20029443, DOI: 10.1038/nrclinonc.2009.174.
VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumabCarbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab Lung Cancer 2009, 69: 337-340. PMID: 20036440, PMCID: PMC2891357, DOI: 10.1016/j.lungcan.2009.11.019.
Abstract A4: Phase I clinical trial evaluating the safety, pharmacokinetics and biological effect of intravenous bevacizumab (avastin) in combination with escalating doses of AZD2171 (cediranib) administered orally for 21 consecutive days to patients with advanced malignancies (NCI protocol #7534)Hong D, Davis D, Naing A, Fu S, Falchook G, Ricks L, Bekele N, Mittleman D, Liu W, Ivy P, Herbst R, Kurzrock R. Abstract A4: Phase I clinical trial evaluating the safety, pharmacokinetics and biological effect of intravenous bevacizumab (avastin) in combination with escalating doses of AZD2171 (cediranib) administered orally for 21 consecutive days to patients with advanced malignancies (NCI protocol #7534) Molecular Cancer Therapeutics 2009, 8: a4-a4. DOI: 10.1158/1535-7163.targ-09-a4.
Abstract B139: Molecular pharmacology and antitumor activity of PHT-427 a novel AKT/PDPK1 pleckstrin homology domain inhibitorPowis G, Moses S, Zhang S, Du-Cuny L, Song Z, Herbst R, Jacoby J, Kirkpatrick L, Mash E, Meuillet E. Abstract B139: Molecular pharmacology and antitumor activity of PHT-427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor Molecular Cancer Therapeutics 2009, 8: b139-b139. DOI: 10.1158/1535-7163.targ-09-b139.
Evolving Treatment Algorithms for Advanced Non–Small-Cell Lung Cancer: 2009 Looking Toward 2012Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. Evolving Treatment Algorithms for Advanced Non–Small-Cell Lung Cancer: 2009 Looking Toward 2012 Clinical Lung Cancer 2009, 10: 392-394. PMID: 19900855, DOI: 10.3816/clc.2009.n.074.
9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trialEberhardt W, Johnson B, Sun Y, Germonpré P, Saijo N, Zhou C, Wang J, Tada H, Kennedy S, Herbst R. 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial European Journal Of Cancer Supplements 2009, 7: 505. DOI: 10.1016/s1359-6349(09)71714-8.
Integration of Molecular Profiling into the Lung Cancer ClinicPao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ. Integration of Molecular Profiling into the Lung Cancer Clinic Clinical Cancer Research 2009, 15: 5317-5322. PMID: 19706816,

Roy S. Herbst, MD, PhD

Contact Information

Related Links

Patient Care

Research & Publications

Biography

News

Research Summary

Coauthors

Research Interests

Public Health Interests

Selected Publications